A Phase 2 interventional study of Elinzanetant (BAY3427080) and Placebo in Menopause, Hot Flashes and Night Waking, sponsored by Bayer. Completed at 25 sites in 3 countries. Open to female participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-03-10.
Sponsored by Bayer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing elinzanetant in Hot Flashes — none open to participants now, 1 under way, 1 of them phase 3. elinzanetant · Hot Flashes.
Among the 13 studies testing elinzanetant in Hot Flashes, this one is the 5th largest by enrollment, is the only one that started in 2018, is the only one in phase 2, and was the 2nd registered.
339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.
Browse Hot Flashes studies →None of the 13 studies testing elinzanetant in Hot Flashes is open now. The open studies under Hot Flashes, anywhere →
elinzanetant: first FDA approval 2025 (LYNKUET), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →
Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 40 Years to 65 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 2 · Phase 3 4
First in 2016; this study’s year is marked. 1 started in 2018.
This study's enrollment of 199 is above the median of 90 across 306 interventional studies indexed under Hot Flashes.
Median enrollment 64 across the 13 interventional studies. Of the 12 that completed or were terminated, 5 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 13 have an industry lead sponsor. The 1 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
18 studies in Hot Flashes by Bayer: none open now, 1 under way, 1 of them phase 3. Of 17 finished, 7 (41%) have results posted.
Among the 18 studies in Hot Flashes by Bayer, this one is the 8th largest by enrollment, is the only one that started in 2018, is one of 2 in phase 2, and was the 7th registered.
Bayer’s Hot Flashes studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing elinzanetant in Hot Flashes, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bayer’s 18 in Hot Flashes:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the effectiveness of BAY3427080 (NT-814), taken once a day, in the treatment of troublesome post-menopausal symptoms.
This is a multi-centre, multi-country, double-blind, randomised, placebo-controlled Phase 2b study. The study will have a single-blind run-in period and will be adaptive with respect to the number of subjects recruited into each dose group. Four doses of BAY3427080 (40 mg once a day, 80 mg once a day, 120 mg once a day and 160 mg once a day) will be investigated and compared to placebo, in five parallel groups. Subjects will participate in the study for a total of approximately 19 weeks, comprising a screening period of 1 week, a 14 week treatment period, and then a final follow up visit 4 weeks after the end of the treatment period. There will be a total of 8 visits whilst participating in the study. Subjects will record their hot flashes in an electronic diary during the screening period to establish eligibility and throughout the study after randomisation.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 4x40 mg elinzanetant capsules.
Drug: Elinzanetant (BAY3427080)
Participants received 3x40 mg elinzanetant capsules and 1 placebo capsule.
Drug: Elinzanetant (BAY3427080)
Participants received 2x40 mg elinzanetant capsules and 2 placebo capsules.
Drug: Elinzanetant (BAY3427080)
Participants received one 40 mg elinzanetant capsule and 3 placebo capsules.
Drug: Elinzanetant (BAY3427080)
Participants received four placebo capsules orally once daily in the evening before bedtime.
Drug: Placebo
BAY3427080 capsules
Also known as: NT-814
Placebo capsules
Mean Change From Baseline in Mean Daily Frequency of Moderate and Severe Hot Flushes From Baseline to Week 4
Participants recorded daily in their electronic diary (eDiary) the frequency and severity of hot flushes during the treatment period. The baseline assessment for hot flushes was calculated using the last 7 days (not necessarily consecutive days) with an available data in the evening and/or the morning of the baseline diary completion period. A diary day was comprised of the evening entry of this day and the morning entry of the following day, in that order. Mean daily frequency = Sum of number of hot flushes filled in the diary during the last 7 diary days (with at least one available data in the evening and/or morning) divided by 7. Moderate: Sensation of heat with sweating, but able to continue activity. Severe: Sensation of heat with sweating, causing cessation (stopping) of activity.
Time frame: From baseline to Week 4
Mean Change From Baseline in Mean Daily Frequency of Moderate and Severe Hot Flushes From Baseline to Week 12
Participants recorded daily in their electronic diary (eDiary) the frequency and severity of hot flushes during the treatment period. The baseline assessment for hot flushes was calculated using the last 7 days (not necessarily consecutive days) with an available data in the evening and/or the morning of the baseline diary completion period. A diary day was comprised of the evening entry of this day and the morning entry of the following day, in that order. Mean daily frequency = Sum of number of hot flushes filled in the diary during the last 7 diary days (with at least one available data in the evening and/or morning) divided by 7. Moderate: Sensation of heat with sweating, but able to continue activity. Severe: Sensation of heat with sweating, causing cessation (stopping) of activity.
Time frame: From baseline to Week 12
Mean Change From Baseline in Mean Severity of Moderate and Severe Hot Flushes From Baseline to Week 4
Participants recorded daily in their eDiary the frequency and severity of hot flushes during the treatment period. Mean weekly severity = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). Severity is graded by the women from 1 to 3 (1 = mild; 2 = moderate; 3 = severe).
Time frame: From baseline to Week 4
Mean Change From Baseline in Mean Severity of Moderate and Severe Hot Flushes From Baseline to Week 12
Participants recorded daily in their eDiary the frequency and severity of hot flushes during the treatment period. Mean weekly severity = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). Severity was graded by the women from 1 to 3 (1 = mild; 2 = moderate; 3 = severe).
Time frame: From baseline to Week 12
Mean Change From Baseline in Frequency of Mean Daily Moderate and Severe Hot Flushes From Baseline to Weeks 1, 2, 8 and 16
Participants recorded daily in their electronic diary (eDiary) the frequency and severity of hot flushes during the treatment period. The baseline assessment for hot flushes was calculated using the last 7 days (not necessarily consecutive days) with an available data in the evening and/or the morning of the baseline diary completion period. A diary day was comprised of the evening entry of this day and the morning entry of the following day, in that order. Mean daily frequency = Sum of number of hot flushes filled in the diary during the last 7 diary days (with at least one available data in the evening and/or morning) divided by 7. Moderate: Sensation of heat with sweating, but able to continue activity. Severe: Sensation of heat with sweating, causing cessation (stopping) of activity.
Time frame: From baseline to Weeks 1, 2, 8 and 16
Mean Change From Baseline in Mean Severity of Moderate and Severe Hot Flushes From Baseline to Weeks 1, 2, 8 and 16
Participants recorded daily in their diary the frequency and severity of hot flushes during the treatment period. Mean weekly severity = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). Severity is graded by the women from 1 to 3 (1 = mild; 2 = moderate; 3 = severe).
Time frame: From baseline to Weeks 1, 2, 8 and 16
Mean Change From Baseline in Mean Daily Frequency of All Hot Flushes From Baseline to Weeks 1, 2, 4, 8, 12 and 16
Participants recorded daily in their electronic diary (eDiary) the frequency and severity of hot flushes during the treatment period. The baseline assessment for hot flushes was calculated using the last 7 days (not necessarily consecutive days) with an available data in the evening and/or the morning of the baseline diary completion period. A diary day was comprised of the evening entry of this day and the morning entry of the following day, in that order. Mean daily frequency = Sum of number of hot flushes filled in the diary during the last 7 diary days (with at least one available data in the evening and/or morning) divided by 7. Moderate: Sensation of heat with sweating, but able to continue activity. Severe: Sensation of heat with sweating, causing cessation (stopping) of activity.
Time frame: From baseline to Weeks 1, 2, 4, 8, 12 and 16
Mean Change From Baseline in Mean Severity of All Hot Flushes From Baseline to Weeks 1, 2, 4, 8, 12 and 16
Participants recorded daily in their diary the frequency and severity of hot flushes during the treatment period. Mean weekly severity = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). Severity is graded by the women from 1 to 3 (1 = mild; 2 = moderate; 3 = severe).
Time frame: From baseline to Weeks 1, 2, 4, 8, 12 and 16
Mean Change From Baseline in the Mean Daily Hot Flush Score (Frequency x Severity) at Weeks 1, 2, 4, 8, 12 and 16
Mean daily Hot Flushes score = Sum of (frequency x severity) filled in the diary during the last 7 days (with at least one available data in the evening and/or morning) divided by 7. Severity is graded by the women from 1 to 3 (1 = mild; 2 = moderate; 3 = severe).
Time frame: From baseline to Weeks 1, 2, 4, 8, 12 and 16
Number of Participants With ≥50% and ≥80% Reduction From Baseline in Mean Daily Hot Flushes Frequency at Week 12
The percent change from baseline at a visit Week 12 was calculated. Percent change = (change from baseline in mean daily frequency of moderate and severe hot flushes from baseline to Week 12 / Mean daily frequency of moderate and severe hot flushes at baseline) \* 100. A participant was considered as a responder with a reduction of ≥50% (or ≥80%) if the percent change was ≤-50 (or ≤-80).
Time frame: Week 12
Mean Change From Baseline in Number of All Night-time Awakenings (NTA) at Weeks 1, 2, 4, 8, 12 and 16
Participants were provided with an eDiary to document the number of night-time awakenings (NTA). Each evening, participants recorded the total number of hot flushes of each severity experienced that day since waking. Each morning upon waking, subjects recorded the number of times they woke up in the night and the total number of hot flushes of each severity experienced during the night.
Time frame: From baseline to Weeks 1, 2, 4, 8, 12 and 16
Mean Change From Baseline in Mean Daily Number of NTAs Secondary to Hot Flushes at Weeks 1, 2, 4, 8, 12 and 16
Subjects were provided with an eDiary to document the number of night-time awakenings (NTA). Each evening, subjects recorded the total number of hot flashes of each severity experienced that day since waking. Each morning upon waking, subjects recorded the number of times they woke up in the night and the total number of hot flushes of each severity experienced during the night. Night-time awakenings secondary to hot flashes corresponded to severe hot flash recorded on the morning diary, and all NTAs corresponded to the data recorded in the "Total number of times you woke up last night?" field from the eDiary recorded in the morning. Number of NTAs secondary to hot flushes could not be higher than the number of all NTAs.
Time frame: From baseline to Weeks 1, 2, 4, 8, 12 and 16
Change From Baseline in the Global and Individual Domain Scores of the Pittsburgh Sleep Quality Index (PSQI) at Weeks 4, 8, 12 and 16
The PSQI is a self-rated questionnaire which assesses sleep quality and disturbances over a 1-month time interval. The PSQI uses 19 individual items to generate seven "component" scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction, each scored 0 (no difficulty) to 3 (severe difficulty). The sum of scores for these seven components yields one global score (range 0 to 21). Higher scores indicated worse sleep quality.
Time frame: From baseline to Weeks 4, 8, 12 and 16
Change From Baseline in the Insomnia Severity Index (ISI) Score at Weeks 4, 8, 12 and 16
The ISI is a brief self-report questionnaire assessing the nature, severity, and impact of insomnia. The ISI comprises seven items assessing the perceived severity of difficulties initiating sleep, staying asleep, and early morning awakenings, satisfaction with current sleep pattern, interference with daily functioning, noticeability of impairment attributed to the sleep problem, and degree of distress or concern caused by the sleep problem. Participants rated each item on a scale of 0 to 4, yielding a total score ranging from 0 to 28. The total score was calculated by adding the scores for all seven items. Higher scores indicated severe insomnia.
Time frame: From baseline to Weeks 4, 8, 12 and 16
Change From Baseline in the Hot Flush Related Daily Interference Scale (HFRDIS) Scores at Weeks 2, 4, 8, 12 and 16
The HFRDIS is a 10-item, self-report questionnaire assessing the impact of hot flushes on a woman's life during the past week. For each of the 10 items, participants rated how much hot flushes had interfered with that aspect of their life on a scale of 0 (not at all) to 10 (very much so). The total score was calculated by adding the scores for all 10 items. Higher scores indicated greater interference.
Time frame: From baseline to Weeks 2, 4, 8, 12 and 16
Change From Baseline in the Menopause-specific Quality-of-Life Questionnaire Intervention Version (MenQoL-I) Scores at Weeks 4, 8, 12 and 16
The MenQoL-I is a validated questionnaire used to measure condition-specific quality of life in menopausal women. It is composed of 32 items across four domains (physical, vasomotor, psychosocial and sexual). For each item, participants recorded whether they had experienced the problem in the past month, and if so, they rated how bothered they were by the problem on a scale of 0 (not at all bothered) to 6 (extremely bothered). The item scores were converted to a score ranging from 1 to 8. Domain scores are calculated by averaging the converted individual item scores (range 1-8) related to the respective domain. (Domains: Vasomotor - items 1 to 3, Psychosocial - items 4 to 10, Physical- items 11- to 26, Sexual - items 27 to 29). For a MENQOL total score the aggregated mean of the mean domain scores is calculated. Higher scores indicate greater bother.
Time frame: From baseline to Weeks 4, 8, 12 and 16;
Change From Baseline in the Beck Depression Inventory II (BDI-II) Scores at Weeks 2, 4, 8, 12 and 16
The BDI-II is a 21-item questionnaire assessing the intensity of depressive symptoms over the past 2 weeks. It is composed of items relating to symptoms of depression such as hopelessness and irritability, cognitions such as guilt or feelings of being punished, as well as physical symptoms such as fatigue, weight loss, and lack of interest in sex. Participants rated each item on a scale of 0 to 3 to give a total score ranging from 0 to 63, with a higher score suggesting more severe depressive symptoms.
Time frame: From baseline to Weeks 2, 4, 8, 12 and 16
Plasma Elinzanetant Concentrations at Weeks 2, 4, 8 ,12
Blood samples for analysis of plasma elinzanetant concentrations were collected at Weeks 2, 4, 8, and 12. A small number of participants had elinzanetant concentrations below the LOQ for the assay (1.5 ng/mL) at two or more visits (three participants in each of the 40 mg, 120 mg, and 160 mg groups, four in 80 mg group), indicating that these subjects were non compliant with treatment.
Time frame: At Weeks 2, 4, 8 ,12
Nature and Severity of Adverse Events
A Treatment-Emergent Adverse Events (TEAE) is defined as any adverse event (serious and non-serious) with the onset date on or after the date of first dosing with study treatment. Safety Analysis Set.
Time frame: Up to Week 16
Withdrawals Due to an Adverse Event
A Treatment-Emergent Adverse Events (TEAE) is defined as any adverse event (serious and non-serious) with the onset date on or after the date of first dosing with study treatment.
Time frame: Up to Week 16
Number of Subjects Used Concomitant Medications
A concomitant medication is defined as any medication used on or after date and time of first randomised treatment. All concomitant medications taken during the study were recorded in the eCRF. Any medication that was not specifically prohibited was allowed. (1) Antidiarrheals, intestinal antiinflammatory/antiinfective agents.
Time frame: Up to Week 16
Change From Baseline in Vital Signs (Systolic Blood Pressure) at Weeks 2, 4, 8, 12 and 16
Vital signs, including systolic and diastolic blood pressure, pulse rate, temperature, weight, waist circumference, and height, were measured at the time points and recorded in the eCRF. All vital signs were reviewed by the Investigator or delegated physician.
Time frame: From baseline to Weeks 2, 4, 8, 12 and 16
Change From Baseline in Vital Signs (Diastolic Blood Pressure) at Weeks 2, 4, 8, 12 and 16
Vital signs, including systolic and diastolic blood pressure were measured at the time points and recorded in the eCRF. All vital signs were reviewed by the Investigator or delegated physician.
Time frame: From baseline to Weeks 2, 4, 8, 12 and 16
Change From Baseline in Vital Signs (Pulse Rate) at Weeks 2, 4, 8, 12 and 16
Vital signs, including systolic and diastolic blood pressure, pulse rate, temperature, weight, waist circumference, and height, were measured at the time points and recorded in the eCRF. All vital signs were reviewed by the Investigator or delegated physician.
Time frame: From baseline to Weeks 2, 4, 8, 12 and 16
Change From Baseline in Vital Signs (Temperature) at Weeks 2, 4, 8, 12 and 16
Vital signs, including systolic and diastolic blood pressure, pulse rate, temperature, weight, waist circumference, and height, were measured at the time points and recorded in the eCRF. All vital signs were reviewed by the Investigator or delegated physician.
Time frame: From baseline to Weeks 2, 4, 8, 12 and 16
Change From Baseline in Vital Signs (Weight) at Weeks 2, 4, 8, 12 and 16
Vital signs, including systolic and diastolic blood pressure, pulse rate, temperature, weight, waist circumference, and height, were measured at the time points and recorded in the eCRF. All vital signs were reviewed by the Investigator or delegated physician.
Time frame: From baseline to Weeks 2, 4, 8, 12 and 16
Change From Baseline in Vital Signs (Body Mass Index ) at Weeks 2, 4, 8, 12 and 16
Vital signs, including systolic and diastolic blood pressure, pulse rate, temperature, weight, waist circumference, and height, were measured at the time points and recorded in the eCRF. All vital signs were reviewed by the Investigator or delegated physician.
Time frame: From baseline to Weeks 2, 4, 8, 12 and 16
Change From Baseline in Vital Signs (Waist Circumference) at Weeks 2, 4, 8, 12 and 16
Vital signs, including systolic and diastolic blood pressure, pulse rate, temperature, weight, waist circumference, and height, were measured at the time points and recorded in the eCRF. All vital signs were reviewed by the Investigator or delegated physician.
Time frame: From baseline to Weeks 2, 4, 8, 12 and 16
Number of Subjects With Normal Electrocardiogram (ECG) Findings at Each Visit
All ECGs were performed after the subject had rested for 5 minutes in a semi-recumbent position. All ECG reports were reviewed, signed and dated by the Investigator or delegated physician. Reported results are cardiovascular system-examination findings. Normal ECG was decided by investigator. The findings are presented as Normal ECG.
Time frame: At Weeks 2, 4, 8, 12 and 16
Number of Subjects With Abnormal Not Clinically Significant ECG Findings at Each Visit
All ECGs were performed after the subject had rested for 5 minutes in a semi-recumbent position. All ECG reports were reviewed, signed and dated by the Investigator or delegated physician. Reported results are cardiovascular system-examination findings. Abnormal not clinically significant ECG findings were decided by investigator. The findings are presented as Abnormal not clinically significant ECG.
Time frame: At Weeks 2, 4, 8, 12 and 16
Number of Subjects With Abnormal Clinically Significant ECG Findings at Each Visit
All ECGs were performed after the subject had rested for 5 minutes in a semi-recumbent position. All ECG reports were reviewed, signed and dated by the Investigator or delegated physician. Reported results are cardiovascular system-examination findings. Abnormal clinically significant ECG findings were decided by investigator. The findings are presented as Abnormal clinically significant ECG.
Time frame: At Weeks 2, 4, 8, 12 and 16
Change From Baseline at Weeks 2, 4, 8, 12 and 16 in ECG Intervals (RR)
All ECGs were performed after the subject had rested for 5 minutes in a semi-recumbent position. The same model of ECG recorder was used throughout the study for any given subject wherever possible. All ECG reports were reviewed, signed and dated by the Investigator or delegated physician. Reports were then filed with the subject's medical record. In categories the number of subjects analyzed (N) for each week is mentioned for each reporting group respectively.
Time frame: At Weeks 2, 4, 8, 12 and 16
Change From Baseline at Weeks 2, 4, 8, 12 and 16 in ECG Intervals (PR)
All ECGs were performed after the subject had rested for 5 minutes in a semi-recumbent position. The same model of ECG recorder was used throughout the study for any given subject wherever possible. All ECG reports were reviewed, signed and dated by the Investigator or delegated physician. Reports were then filed with the subject's medical record.
Time frame: At Weeks 2, 4, 8, 12 and 16
Change From Baseline at Weeks 2, 4, 8, 12 and 16 in ECG Intervals (QT)
All ECGs were performed after the subject had rested for 5 minutes in a semi-recumbent position. The same model of ECG recorder was used throughout the study for any given subject wherever possible. All ECG reports were reviewed, signed and dated by the Investigator or delegated physician. Reports were then filed with the subject's medical record.
Time frame: At Weeks 2, 4, 8, 12 and 16
Change From Baseline at Weeks 2, 4, 8, 12 and 16 in ECG Intervals (QTc)
All ECGs were performed after the subject had rested for 5 minutes in a semi-recumbent position. The same model of ECG recorder was used throughout the study for any given subject wherever possible. All ECG reports were reviewed, signed and dated by the Investigator or delegated physician. Reports were then filed with the subject's medical record. QTc: QT corrected interval.
Time frame: At Weeks 2, 4, 8, 12 and 16
Change From Baseline at Weeks 2, 4, 8, 12 and 16 in ECG Intervals (QTcF)
All ECGs were performed after the subject had rested for 5 minutes in a semi-recumbent position. The same model of ECG recorder was used throughout the study for any given subject wherever possible. All ECG reports were reviewed, signed and dated by the Investigator or delegated physician. Reports were then filed with the subject's medical record. QTcF: QT interval with Fridericia's correction.
Time frame: At Weeks 2, 4, 8, 12 and 16
Number of Subjects With Absolute QTcF Values by Category at Each Visit: ≤450, >450 to ≤480, >480 to ≤500, >500 Msec
Absolute QTcF values reported.
Time frame: From baseline to Weeks 2, 4, 8, 12 and 16
Number of Subjects With Change From Baseline in ECG QTcF Values by Category at Weeks 2, 4, 8, 12 and 16: ≤0, >0 to ≤30, >30 to ≤60, >60 Msec
Increase from Baseline overtime was reported.
Time frame: From baseline to Weeks 2, 4, 8, 12 and 16
Change From Baseline in the Electronic Columbia Suicide Severity Rating Scale (eC-SSRS) at Weeks 4, 12 and 16
The Columbia Suicide Severity Rating Scale (C-SSRS) is a rating scale created to evaluate suicidality in adults and children over the age of 12. It rates an individual's degree of suicidal ideation on a scale, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent." The version used was the eC-SSRS, which is a subject-reported version of the scale. Shifts from baseline versus post-baseline to demonstrate changes in categories (cat) were reported using cat 1 (No Suicidal Ideation or Behaviour), cat 2 (Suicidal Ideation) and cat 3 (Suicidal Behaviour).
Time frame: Baseline to Weeks 4, 12 and 16
Change From Baseline at Weeks 2, 4, 12 and 16 for Clinical Laboratory Parameters Hematology: Erythrocytes
Blood samples for clinical hematology assessment were collected and sent to the central laboratory for analysis.
Time frame: From baseline to Weeks 2, 4, 12 and 16
Change From Baseline at Weeks 2, 4, 12 and 16 for Clinical Laboratory Parameters Hematology: Hematocrit
Blood samples for clinical hematology assessment were collected and sent to the central laboratory for analysis.
Time frame: From baseline to Weeks 2, 4, 12 and 16
Change From Baseline at Weeks 2, 4, 12 and 16 in Clinical Laboratory Parameters Hematology: Hemoglobin
Blood samples for clinical hematology assessment were collected and sent to the central laboratory for analysis.
Time frame: From baseline to Weeks 2, 4, 12 and 16
Change From Baseline at Weeks 2, 4, 12 and 16 in Clinical Laboratory Parameters Hematology: Erythrocytes Mean Corpuscular Volume
Blood samples for clinical hematology assessment were collected and sent to the central laboratory for analysis.
Time frame: From baseline to Weeks 2, 4, 12 and 16
Change From Baseline at Weeks 2, 4, 12 and 16 in Clinical Laboratory Parameters Hematology: Leukocytes, Platelets, Basophils, Eosinophils, Lymphocytes, Monocytes and Neutrophils
Blood samples for clinical hematology assessment were collected and sent to the central laboratory for analysis.
Time frame: From baseline to Weeks 2, 4, 12 and 16
Change From Baseline at Weeks 2, 4, 12 and 16 in Clinical Laboratory Parameters Hematology: Leukocytes, Basophils, Eosinophils, Lymphocytes, Monocytes and Neutrophils
Blood samples for clinical hematology assessment were collected and sent to the central laboratory for analysis.
Time frame: From baseline to Weeks 2, 4, 12 and 16
Change From Baseline at Weeks 2, 4, 8, 12 and 16 in Clinical Laboratory Parameters Biochemistry: Sodium, Potassium, Glucose, Urea Nitrogen, Calcium, Phosphate, Bicarbonate, Magnesium and Chloride
Blood samples for clinical chemistry assessment were collected and sent to the central laboratory for analysis.
Time frame: From baseline to Weeks 2, 4, 8, 12 and 16
Change From Baseline at Weeks 2, 4, 8, 12 and 16 in Clinical Laboratory Parameters Biochemistry: Creatinine and Bilirubin
Blood samples for clinical chemistry assessment were collected and sent to the central laboratory for analysis.
Time frame: From baseline to Weeks 2, 4, 8, 12 and 16
Change From Baseline at Weeks 2, 4, 8, 12 and 16 in Clinical Laboratory Parameters Biochemistry: Creatinine Kinase, Alkaline Phosphatase, Aspartate Aminotransferase, Alanine Aminotransferase and Gamma Glutamyl Transferase
Blood samples for clinical chemistry assessment were collected and sent to the central laboratory for analysis.
Time frame: From baseline to Weeks 2, 4, 8, 12 and 16
Change From Baseline at Weeks 2, 4, 8, 12 and 16 in Clinical Laboratory Parameters Biochemistry: Protein and Albumin
Blood samples for clinical chemistry assessment were collected and sent to the central laboratory for analysis.
Time frame: From baseline to Weeks 2, 4, 8, 12 and 16
Change From Baseline at Weeks 2, 4, 8, 12 and 16 in Clinical Laboratory Parameters Biochemistry: Hemoglobin A1C
Blood samples for clinical chemistry assessment were collected and sent to the central laboratory for analysis.
Time frame: From baseline to Weeks 2, 4, 8, 12 and 16
Change From Baseline at Weeks 12 and 16 in Clinical Laboratory Parameters Bone: Bone Specific Alkaline Phosphatase and Procollagen 1 N-Terminal Propeptide
Blood for assessment of bone turnover markers was collected and sent to the central laboratory for analysis.
Time frame: From baseline to Weeks 12 and 16
Change From Baseline at Weeks 2, 4, 12 and 16 in Clinical Laboratory Parameters Urinalysis: pH
Urine for urinalysis was collected and sent to the central laboratory for analysis. Urine pH was measured on a pH scale.
Time frame: From baseline to Weeks 2, 4, 12 and 16
Change From Baseline at Weeks 2, 4, 12 and 16 in Clinical Laboratory Parameters Urinalysis: Specific Gravity
Urine for urinalysis was collected and sent to the central laboratory for analysis.
Time frame: From baseline to Weeks 2, 4, 12 and 16
Change From Baseline at Weeks 2, 4, 12 and 16 in Clinical Laboratory Parameters Urinalysis: Glucose, Bilirubin, Ketones, Occult Blood, Protein, Urobilinogen and Nitrite
Urine for urinalysis was collected and sent to the central laboratory for analysis. Clinical relevance was judged by the investigator. Assessment was done using standard laboratory practice. For evaluation of the chemical properties of the urine sample test strips were used which have test pads of chemicals that change color when they come in contact with reagents. The degree of color change correlates with the amount of reagent present. Each color block represents a range of values. Range and direction of scores for reagents nitrite and urobilinogen: negative = normal; positive = abnormal. Range and direction of scores for all other reagents tested: negative = normal; trace, 1+, 2+, 3+ = abnormal, the higher the value, the higher the concentration of the reagent tested.
Time frame: From baseline to Weeks 2, 4, 12 and 16
Change From Baseline at Weeks 2, 4, 12 and 16 in Clinical Laboratory Parameters Urinalysis: Erythrocytes and Leukocytes
Urine for urinalysis was collected and sent to the central laboratory for analysis. Results are reported according to the amount present in the microscope's field of view at high magnification (/HPF \[high-power field\]).
Time frame: From baseline to Weeks 2, 4, 12 and 16
Change From Baseline at Weeks 2, 4, 12 and 16 in Clinical Laboratory Parameters Urinalysis: Hyaline Casts
Urine for urinalysis was collected and sent to the central laboratory for analysis. Results are reported according to the amount present in the microscope's field of view at low magnification (/LPF \[low-power field\]).
Time frame: From baseline to Weeks 2, 4, 12 and 16
Change From Baseline at Weeks 2, 4, 12 and 16 in Clinical Laboratory Parameters Urinalysis: Bacteria, Yeast Cells, Granular Casts, RBC Casts, Waxy Casts, WBC Casts, Calcium Oxalate Crystals, Triple Phosphate Crystals and Uric Acid Crystals
Urine for urinalysis was collected and sent to the central laboratory for analysis. The evaluation of components in the urine samples such as bacteria, yeast, red blood cells (RBC), white blood cells (WBC), casts and crystals was performed by microscopy. Results are reported according to the amount present in the microscope's field of view at low magnification (/LPF \[low-power field\]) and high magnification (/HPF \[high-power field\]). Range and direction of scores microscopic identification of urine components: * Bacteria: none seen, 1+, 2+, 3+,4+, TNTC (too numerous to count). * Other urine components: none seen=normal; few, moderate, many, TNTC = abnormal. The higher the value, the higher the concentration of the component evaluated.
Time frame: From baseline to Weeks 2, 4, 12 and 16
The study was conducted between 20 November 2018 (first participant, first visit) and 21 November 2019 (last participant, last visit) at 11 sites in the USA, nine sites in the UK, and five sites in Canada.
| Milestone | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Started | 47 | 31 | 17 | 52 | 52 |
| Completed | 43 | 30 | 16 | 51 | 45 |
| Not completed | 4 | 1 | 1 | 1 | 7 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 2 | 0 | 1 | 0 | 5 |
| Withdrew: Withdrawal by subject | 2 | 1 | 0 | 1 | 1 |
Participants recorded daily in their electronic diary (eDiary) the frequency and severity of hot flushes during the treatment period. The baseline assessment for hot flushes was calculated using the last 7 days (not necessarily consecutive days) with an available data in the evening and/or the morning of the baseline diary completion period. A diary day was comprised of the evening entry of this day and the morning entry of the following day, in that order. Mean daily frequency = Sum of number of hot flushes filled in the diary during the last 7 diary days (with at least one available data in the evening and/or morning) divided by 7. Moderate: Sensation of heat with sweating, but able to continue activity. Severe: Sensation of heat with sweating, causing cessation (stopping) of activity.
| Hot flushes per day | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline | 11.82 ± 4.42 | 12.13 ± 8.81 | 14.55 ± 5.87 | 13.54 ± 7.17 | 12.92 ± 6.90 |
| Week 4: Change from baseline | -2.45 ± 3.65 | -4.19 ± 5.78 | -4.30 ± 6.45 | -6.76 ± 5.85 | -5.42 ± 5.36 |
Participants recorded daily in their electronic diary (eDiary) the frequency and severity of hot flushes during the treatment period. The baseline assessment for hot flushes was calculated using the last 7 days (not necessarily consecutive days) with an available data in the evening and/or the morning of the baseline diary completion period. A diary day was comprised of the evening entry of this day and the morning entry of the following day, in that order. Mean daily frequency = Sum of number of hot flushes filled in the diary during the last 7 diary days (with at least one available data in the evening and/or morning) divided by 7. Moderate: Sensation of heat with sweating, but able to continue activity. Severe: Sensation of heat with sweating, causing cessation (stopping) of activity.
| Hot flushes per day | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline | 11.82 ± 4.42 | 12.13 ± 8.81 | 14.55 ± 5.87 | 13.54 ± 7.17 | 12.92 ± 6.90 |
| Week 12: Change from baseline | -4.49 ± 4.29 | -6.48 ± 7.82 | -5.49 ± 5.31 | -7.91 ± 6.66 | -6.57 ± 5.83 |
Participants recorded daily in their eDiary the frequency and severity of hot flushes during the treatment period. Mean weekly severity = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). Severity is graded by the women from 1 to 3 (1 = mild; 2 = moderate; 3 = severe).
| Hot flushes per day | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline | 2.54 ± 0.20 | 2.51 ± 0.26 | 2.63 ± 0.24 | 2.54 ± 0.24 | 2.54 ± 0.26 |
| Week 4: Change from baseline | -0.31 ± 0.41 | -0.38 ± 0.54 | -0.44 ± 0.56 | -0.51 ± 0.57 | -0.54 ± 0.67 |
Participants recorded daily in their eDiary the frequency and severity of hot flushes during the treatment period. Mean weekly severity = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). Severity was graded by the women from 1 to 3 (1 = mild; 2 = moderate; 3 = severe).
| Hot flushes per day | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline | 2.54 ± 0.20 | 2.51 ± 0.26 | 2.63 ± 0.24 | 2.54 ± 0.24 | 2.54 ± 0.26 |
| Week 12: Change from baseline | -0.41 ± 0.50 | -0.53 ± 0.64 | -0.26 ± 0.45 | -0.56 ± 0.68 | -0.73 ± 0.78 |
Participants recorded daily in their electronic diary (eDiary) the frequency and severity of hot flushes during the treatment period. The baseline assessment for hot flushes was calculated using the last 7 days (not necessarily consecutive days) with an available data in the evening and/or the morning of the baseline diary completion period. A diary day was comprised of the evening entry of this day and the morning entry of the following day, in that order. Mean daily frequency = Sum of number of hot flushes filled in the diary during the last 7 diary days (with at least one available data in the evening and/or morning) divided by 7. Moderate: Sensation of heat with sweating, but able to continue activity. Severe: Sensation of heat with sweating, causing cessation (stopping) of activity.
| Hot flushes per day | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline | 11.82 ± 4.42 | 12.13 ± 8.81 | 14.55 ± 5.87 | 13.54 ± 7.17 | 12.92 ± 6.90 |
| Week 1: Change from baseline | -1.22 ± 3.07 | -1.61 ± 3.05 | -1.63 ± 3.56 | -3.22 ± 3.43 | -3.09 ± 3.76 |
| Week 2: Change from baseline | -2.19 ± 4.01 | -3.03 ± 3.95 | -3.47 ± 4.37 | -4.58 ± 4.70 | -3.78 ± 4.48 |
| Week 8: Change from baseline | -4.33 ± 4.79 | -5.72 ± 6.18 | -5.94 ± 5.26 | -7.84 ± 5.95 | -5.58 ± 6.00 |
| Week 16: Change from baseline | -3.95 ± 4.85 | -5.74 ± 9.45 | -2.01 ± 4.99 | -5.95 ± 6.95 | -2.78 ± 6.54 |
Participants recorded daily in their diary the frequency and severity of hot flushes during the treatment period. Mean weekly severity = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). Severity is graded by the women from 1 to 3 (1 = mild; 2 = moderate; 3 = severe).
| Hot flushes per day | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline | 2.54 ± 0.20 | 2.51 ± 0.26 | 2.63 ± 0.24 | 2.54 ± 0.24 | 2.55 ± 0.26 |
| Week 1: Change from baseline | -0.24 ± 0.30 | -0.21 ± 0.20 | -0.22 ± 0.21 | -0.25 ± 0.28 | -0.26 ± 0.26 |
| Week 2: Change from baseline | -0.30 ± 0.39 | -0.32 ± 0.32 | -0.42 ± 0.58 | -0.37 ± 0.46 | -0.40 ± 0.55 |
| Week 8: Change from baseline | -0.45 ± 0.58 | -0.48 ± 0.54 | -0.40 ± 0.61 | -0.51 ± 0.54 | -0.65 ± 0.73 |
| Week 16: Change from baseline | 2.15 ± 0.65 | 2.03 ± 0.56 | 2.50 ± 0.46 | 2.13 ± 0.71 | 2.08 ± 0.62 |
Participants recorded daily in their electronic diary (eDiary) the frequency and severity of hot flushes during the treatment period. The baseline assessment for hot flushes was calculated using the last 7 days (not necessarily consecutive days) with an available data in the evening and/or the morning of the baseline diary completion period. A diary day was comprised of the evening entry of this day and the morning entry of the following day, in that order. Mean daily frequency = Sum of number of hot flushes filled in the diary during the last 7 diary days (with at least one available data in the evening and/or morning) divided by 7. Moderate: Sensation of heat with sweating, but able to continue activity. Severe: Sensation of heat with sweating, causing cessation (stopping) of activity.
| Hot flushes per day | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline | 14.04 ± 5.57 | 14.19 ± 11.01 | 16.55 ± 6.89 | 15.39 ± 7.91 | 15.78 ± 9.62 |
| Week 1 | -1.36 ± 3.03 | -1.72 ± 3.27 | -1.33 ± 5.68 | -3.30 ± 3.99 | -3.69 ± 4.81 |
| Week 2 | -2.35 ± 4.60 | -2.99 ± 4.90 | -2.74 ± 5.97 | -4.57 ± 5.48 | -4.43 ± 5.68 |
| Week 4 | -2.67 ± 4.09 | -4.11 ± 6.31 | -3.45 ± 8.54 | -6.70 ± 6.16 | -5.79 ± 6.09 |
| Week 8 | -4.74 ± 5.57 | -5.65 ± 6.55 | -5.45 ± 6.56 | -7.96 ± 6.16 | -6.03 ± 6.43 |
| Week 12 | -5.07 ± 5.48 | -6.50 ± 8.67 | -5.11 ± 8.41 | -7.94 ± 6.74 | -7.47 ± 7.13 |
| Week 16 | -4.60 ± 6.17 | -5.83 ± 10.86 | -1.76 ± 7.50 | -6.19 ± 7.68 | -3.11 ± 6.71 |
Participants recorded daily in their diary the frequency and severity of hot flushes during the treatment period. Mean weekly severity = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). Severity is graded by the women from 1 to 3 (1 = mild; 2 = moderate; 3 = severe).
| Hot flushes per day | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline | 2.34 ± 0.32 | 2.34 ± 0.35 | 2.46 ± 0.37 | 2.38 ± 0.34 | 2.35 ± 0.39 |
| Week 1: Change from baseline | -0.04 ± 0.23 | -0.04 ± 0.18 | -0.05 ± 0.12 | -0.09 ± 0.25 | -0.07 ± 0.18 |
| Week 2: Change from baseline | -0.10 ± 0.32 | -0.15 ± 0.27 | -0.25 ± 0.52 | -0.21 ± 0.46 | -0.20 ± 0.50 |
| Week 4: Change from baseline | -0.11 ± 0.36 | -0.21 ± 0.47 | -0.27 ± 0.49 | -0.35 ± 0.60 | -0.34 ± 0.63 |
| Week 8: Change from baseline | -0.25 ± 0.54 | -0.31 ± 0.47 | -0.23 ± 0.52 | -0.35 ± 0.55 | -0.44 ± 0.72 |
| Week 12: Change from baseline | -0.21 ± 0.44 | -0.35 ± 0.57 | -0.08 ± 0.41 | -0.41 ± 0.62 | -0.52 ± 0.79 |
| Week 16: Change from baseline | -0.21 ± 0.49 | -0.30 ± 0.52 | 0.05 ± 0.34 | -0.26 ± 0.56 | -0.24 ± 0.54 |
Mean daily Hot Flushes score = Sum of (frequency x severity) filled in the diary during the last 7 days (with at least one available data in the evening and/or morning) divided by 7. Severity is graded by the women from 1 to 3 (1 = mild; 2 = moderate; 3 = severe).
| (units on a scale)*(hot flushes per day) | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline | 32.35 ± 12.24 | 32.84 ± 24.82 | 40.76 ± 17.08 | 36.59 ± 19.88 | 35.73 ± 19.75 |
| Week 1: Change from baseline | -3.09 ± 8.16 | -4.26 ± 7.93 | -4.18 ± 11.27 | -8.44 ± 8.98 | -8.67 ± 10.53 |
| Week 2: Change from baseline | -5.62 ± 11.00 | -7.88 ± 10.77 | -9.08 ± 13.09 | -11.98 ± 12.39 | -10.51 ± 12.47 |
| Week 4: Change from baseline | -6.62 ± 9.79 | -10.68 ± 15.26 | -11.39 ± 18.82 | -17.54 ± 15.50 | -14.20 ± 14.30 |
| Week 8: Change from baseline | -11.63 ± 12.51 | -14.64 ± 16.33 | -16.17 ± 15.32 | -20.54 ± 15.80 | -14.89 ± 15.36 |
| Week 12: Change from baseline | -12.33 ± 11.96 | -16.71 ± 20.60 | -14.93 ± 16.83 | -20.72 ± 17.81 | -17.70 ± 15.38 |
| Week 16: Change from baseline | -10.89 ± 13.45 | -14.93 ± 25.48 | -4.97 ± 14.35 | -15.60 ± 19.03 | -7.50 ± 16.55 |
The percent change from baseline at a visit Week 12 was calculated. Percent change = (change from baseline in mean daily frequency of moderate and severe hot flushes from baseline to Week 12 / Mean daily frequency of moderate and severe hot flushes at baseline) \* 100. A participant was considered as a responder with a reduction of ≥50% (or ≥80%) if the percent change was ≤-50 (or ≤-80).
| Participants | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| >= 50% reduction — Yes | 17 | 20 | 5 | 32 | 30 |
| >= 50% reduction — No | 27 | 10 | 11 | 19 | 13 |
| >=80% reduction — Yes | 8 | 6 | 0 | 16 | 18 |
| >=80% reduction — No | 36 | 24 | 16 | 35 | 25 |
Participants were provided with an eDiary to document the number of night-time awakenings (NTA). Each evening, participants recorded the total number of hot flushes of each severity experienced that day since waking. Each morning upon waking, subjects recorded the number of times they woke up in the night and the total number of hot flushes of each severity experienced during the night.
| Night-time awakenings per day | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline | 3.86 ± 2.06 | 3.44 ± 1.82 | 5.00 ± 1.76 | 3.80 ± 2.20 | 3.85 ± 2.57 |
| Week 1: Change from baseline | -0.65 ± 1.08 | -0.70 ± 1.24 | -0.57 ± 1.57 | -0.91 ± 1.06 | -0.86 ± 1.93 |
| Week 2: Change from baseline | -0.62 ± 1.54 | -0.70 ± 1.20 | -1.09 ± 1.84 | -1.10 ± 1.34 | -1.00 ± 2.10 |
| Week 4: Change from baseline | -0.86 ± 1.40 | -1.05 ± 1.43 | -0.99 ± 2.96 | -1.49 ± 1.43 | -1.03 ± 2.22 |
| Week 8: Change from baseline | -0.99 ± 1.31 | -1.66 ± 1.77 | -1.30 ± 2.15 | -1.79 ± 1.47 | -1.17 ± 2.51 |
| Week 12: Change from baseline | -1.28 ± 1.44 | -1.53 ± 1.89 | -1.61 ± 2.46 | -1.60 ± 1.38 | -1.40 ± 2.40 |
| Week 16: Change from baseline | -1.08 ± 1.30 | -0.96 ± 1.91 | -0.31 ± 2.90 | -1.05 ± 1.30 | -0.32 ± 2.10 |
Subjects were provided with an eDiary to document the number of night-time awakenings (NTA). Each evening, subjects recorded the total number of hot flashes of each severity experienced that day since waking. Each morning upon waking, subjects recorded the number of times they woke up in the night and the total number of hot flushes of each severity experienced during the night. Night-time awakenings secondary to hot flashes corresponded to severe hot flash recorded on the morning diary, and all NTAs corresponded to the data recorded in the "Total number of times you woke up last night?" field from the eDiary recorded in the morning. Number of NTAs secondary to hot flushes could not be higher than the number of all NTAs.
| Night-time awakenings per day | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline | 2.90 ± 1.64 | 2.41 ± 1.57 | 4.05 ± 1.86 | 2.76 ± 1.71 | 2.57 ± 1.54 |
| Week 1: Change from baseline | -0.57 ± 0.96 | -0.52 ± 1.07 | -0.63 ± 1.53 | -0.90 ± 1.03 | -0.68 ± 1.14 |
| Week 2: Change from baseline | -0.69 ± 1.03 | -0.75 ± 1.18 | -1.13 ± 1.89 | -1.18 ± 1.27 | -0.92 ± 1.38 |
| Week 4: Change from baseline | -0.89 ± 1.08 | -0.91 ± 1.26 | -1.33 ± 2.27 | -1.53 ± 1.19 | -1.01 ± 1.62 |
| Week 8: Change from baseline | -1.09 ± 1.36 | -1.50 ± 1.40 | -1.69 ± 2.21 | -1.79 ± 1.35 | -1.13 ± 1.86 |
| Week 12: Change from baseline | -1.31 ± 1.39 | -1.63 ± 1.46 | -1.70 ± 2.53 | -1.67 ± 1.27 | -1.32 ± 1.75 |
| Week 16: Change from baseline | -1.05 ± 1.19 | -1.29 ± 1.63 | -0.45 ± 2.05 | -1.19 ± 1.23 | -0.44 ± 1.62 |
The PSQI is a self-rated questionnaire which assesses sleep quality and disturbances over a 1-month time interval. The PSQI uses 19 individual items to generate seven "component" scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction, each scored 0 (no difficulty) to 3 (severe difficulty). The sum of scores for these seven components yields one global score (range 0 to 21). Higher scores indicated worse sleep quality.
| Units on scale | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline | 10.80 ± 2.39 | 11.94 ± 3.11 | 11.35 ± 3.66 | 10.80 ± 3.00 | 11.44 ± 3.14 |
| Week 4: Change from baseline | -0.63 ± 2.02 | -1.87 ± 2.93 | -1.94 ± 2.68 | -2.70 ± 3.11 | -2.80 ± 2.84 |
| Week 8: Change from baseline | -1.36 ± 2.90 | -2.39 ± 3.63 | -2.38 ± 3.30 | -3.00 ± 3.23 | -3.14 ± 3.37 |
| Week 12: Change from baseline | -1.15 ± 2.95 | -2.47 ± 3.82 | -2.81 ± 2.97 | -3.39 ± 3.12 | -3.54 ± 4.12 |
| Week 16: Change from baseline | -1.85 ± 2.46 | -2.10 ± 3.53 | -1.38 ± 3.26 | -2.24 ± 3.12 | -1.79 ± 2.69 |
The ISI is a brief self-report questionnaire assessing the nature, severity, and impact of insomnia. The ISI comprises seven items assessing the perceived severity of difficulties initiating sleep, staying asleep, and early morning awakenings, satisfaction with current sleep pattern, interference with daily functioning, noticeability of impairment attributed to the sleep problem, and degree of distress or concern caused by the sleep problem. Participants rated each item on a scale of 0 to 4, yielding a total score ranging from 0 to 28. The total score was calculated by adding the scores for all seven items. Higher scores indicated severe insomnia.
| Units on scale | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline | 12.43 ± 5.09 | 13.23 ± 5.36 | 13.24 ± 8.04 | 12.63 ± 5.66 | 13.74 ± 5.89 |
| Week 4: Change from Baseline | -1.60 ± 2.98 | -2.74 ± 4.91 | -3.65 ± 6.03 | -5.14 ± 5.51 | -5.42 ± 5.42 |
| Week 8: Change from Baseline | -1.51 ± 3.64 | -3.74 ± 5.63 | -4.44 ± 6.17 | -6.20 ± 4.93 | -5.72 ± 5.14 |
| Week 12: Change from Baseline | -1.95 ± 4.70 | -3.80 ± 5.45 | -5.81 ± 5.86 | -6.12 ± 5.41 | -7.39 ± 5.82 |
| Week 16: Change from Baseline | -2.65 ± 4.32 | -3.73 ± 6.02 | -3.00 ± 3.72 | -4.34 ± 5.58 | -4.00 ± 5.49 |
The HFRDIS is a 10-item, self-report questionnaire assessing the impact of hot flushes on a woman's life during the past week. For each of the 10 items, participants rated how much hot flushes had interfered with that aspect of their life on a scale of 0 (not at all) to 10 (very much so). The total score was calculated by adding the scores for all 10 items. Higher scores indicated greater interference.
| Units on scale | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline | 52.93 ± 18.40 | 52.74 ± 20.33 | 50.29 ± 21.45 | 53.86 ± 23.42 | 55.36 ± 19.71 |
| Week 2: Change from baseline | -4.00 ± 20.28 | -5.39 ± 21.99 | -11.12 ± 28.14 | -13.75 ± 29.66 | -10.90 ± 21.31 |
| Week 4: Change from baseline | -9.98 ± 20.84 | -13.00 ± 22.53 | -15.06 ± 24.02 | -23.04 ± 28.32 | -18.44 ± 23.37 |
| Week 8: Change from baseline | -15.48 ± 21.07 | -16.26 ± 23.71 | -17.88 ± 27.15 | -26.39 ± 24.90 | -24.09 ± 25.51 |
| Week 12: Change from | -19.37 ± 20.20 | -21.30 ± 22.89 | -15.56 ± 28.70 | -28.33 ± 25.36 | -27.83 ± 24.64 |
| Week 16: Change from baseline | -15.22 ± 21.72 | -10.73 ± 24.87 | -16.69 ± 24.15 | -19.16 ± 22.43 | -12.07 ± 25.94 |
The MenQoL-I is a validated questionnaire used to measure condition-specific quality of life in menopausal women. It is composed of 32 items across four domains (physical, vasomotor, psychosocial and sexual). For each item, participants recorded whether they had experienced the problem in the past month, and if so, they rated how bothered they were by the problem on a scale of 0 (not at all bothered) to 6 (extremely bothered). The item scores were converted to a score ranging from 1 to 8. Domain scores are calculated by averaging the converted individual item scores (range 1-8) related to the respective domain. (Domains: Vasomotor - items 1 to 3, Psychosocial - items 4 to 10, Physical- items 11- to 26, Sexual - items 27 to 29). For a MENQOL total score the aggregated mean of the mean domain scores is calculated. Higher scores indicate greater bother.
| Units on scale | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline | 4.00 ± 1.06 | 4.38 ± 1.16 | 4.47 ± 1.25 | 4.17 ± 1.13 | 4.50 ± 1.23 |
| Week 4: Change from baseline | -0.33 ± 0.90 | -0.62 ± 1.30 | -0.56 ± 0.87 | -1.29 ± 1.14 | -1.13 ± 1.09 |
| Week 8: Change from baseline | -0.62 ± 1.10 | -0.87 ± 1.25 | -0.91 ± 1.06 | -1.45 ± 1.18 | -1.50 ± 0.99 |
| Week 12: Change from baseline | -0.70 ± 1.03 | -0.81 ± 1.44 | -1.09 ± 0.76 | -1.54 ± 1.34 | -1.72 ± 1.32 |
| Week 16: Change from baseline | -0.68 ± 1.01 | -0.76 ± 1.33 | -0.69 ± 0.93 | -1.18 ± 1.13 | -1.00 ± 1.36 |
The BDI-II is a 21-item questionnaire assessing the intensity of depressive symptoms over the past 2 weeks. It is composed of items relating to symptoms of depression such as hopelessness and irritability, cognitions such as guilt or feelings of being punished, as well as physical symptoms such as fatigue, weight loss, and lack of interest in sex. Participants rated each item on a scale of 0 to 3 to give a total score ranging from 0 to 63, with a higher score suggesting more severe depressive symptoms.
| Units on scale | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline | 11.18 ± 8.74 | 14.29 ± 11.36 | 10.47 ± 7.01 | 9.92 ± 8.62 | 11.48 ± 9.30 |
| Week 2: Change from baseline | -1.90 ± 5.29 | -2.23 ± 9.27 | -3.06 ± 7.34 | -3.65 ± 6.95 | -2.71 ± 6.08 |
| Week 4: Change from baseline | -1.55 ± 5.14 | -4.23 ± 9.82 | -2.35 ± 5.16 | -4.08 ± 6.39 | -4.13 ± 6.63 |
| Week 8: Change from baseline | -2.24 ± 5.26 | -5.32 ± 10.13 | -2.00 ± 8.22 | -4.73 ± 6.34 | -5.51 ± 7.14 |
| Week 12: Change from baseline | -1.30 ± 7.22 | -5.00 ± 3.80 | -1.69 ± 7.65 | -4.29 ± 6.56 | -5.73 ± 7.39 |
| Week 16: Change from baseline | -2.43 ± 6.08 | -5.10 ± 11.62 | -0.75 ± 6.71 | -4.04 ± 6.12 | -2.36 ± 8.05 |
Blood samples for analysis of plasma elinzanetant concentrations were collected at Weeks 2, 4, 8, and 12. A small number of participants had elinzanetant concentrations below the LOQ for the assay (1.5 ng/mL) at two or more visits (three participants in each of the 40 mg, 120 mg, and 160 mg groups, four in 80 mg group), indicating that these subjects were non compliant with treatment.
| ng/ml | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|
| Week 2 | 64.254 ± 75.681 | 157.207 ± 93.120 | 292.929 ± 100.381 | 319.552 ± 170.571 |
| Week 4 | 78.946 ± 78.892 | 118.554 ± 175.865 | 253.800 ± 142.944 | 398.389 ± 91.644 |
| Week 8 | 87.985 ± 68.277 | 138.795 ± 72.619 | 226.121 ± 79.171 | 341.673 ± 145.535 |
| Week 12 | 70.138 ± 66.542 | 130.729 ± 414.199 | 197.041 ± 231.390 | 298.896 ± 220.963 |
A Treatment-Emergent Adverse Events (TEAE) is defined as any adverse event (serious and non-serious) with the onset date on or after the date of first dosing with study treatment. Safety Analysis Set.
| Participants | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Number of TEAEs | 28 | 17 | 14 | 34 | 38 |
| Number of TEAEs related to IMP | 7 | 7 | 8 | 8 | 12 |
| Number of Serious TEAEs | 2 | 0 | 1 | 1 | 1 |
| Number of TEAEs leading to death | 0 | 0 | 0 | 0 | 0 |
| Number of Severe TEAEs | 2 | 0 | 1 | 3 | 2 |
A Treatment-Emergent Adverse Events (TEAE) is defined as any adverse event (serious and non-serious) with the onset date on or after the date of first dosing with study treatment.
| Participants | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| TEAEs leading to treatment discontinuation | 1 | 0 | 2 | 0 | 5 |
| TEAEs leading to study discontinuation | 1 | 0 | 1 | 0 | 4 |
A concomitant medication is defined as any medication used on or after date and time of first randomised treatment. All concomitant medications taken during the study were recorded in the eCRF. Any medication that was not specifically prohibited was allowed. (1) Antidiarrheals, intestinal antiinflammatory/antiinfective agents.
| Participants | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Analgesics | 18 | 8 | 9 | 12 | 16 |
| Antiinflammatory and antirheumatic products | 14 | 7 | 5 | 12 | 13 |
| Vitamins | 14 | 6 | 6 | 9 | 14 |
| Drugs for acid related disorders | 13 | 7 | 2 | 10 | 10 |
| Psychoanaleptics | 6 | 5 | 4 | 10 | 9 |
| Psycholeptics | 3 | 7 | 5 | 7 | 7 |
| Antibacterials for systemic use | 9 | 5 | 2 | 5 | 7 |
| Drugs for obstructive airway diseases | 7 | 3 | 3 | 4 | 9 |
| Lipid modifying agents | 3 | 3 | 4 | 8 | 4 |
| Agents acting on the renin-angiotensin system | 7 | 4 | 0 | 11 | 3 |
| Thyroid therapy | 4 | 3 | 3 | 7 | 5 |
| Antihistamines for systemic use | 5 | 4 | 3 | 6 | 3 |
| Antithrombotic agents | 2 | 4 | 2 | 6 | 4 |
| Nasal preparations | 2 | 4 | 1 | 1 | 7 |
| Diuretics | 1 | 2 | 0 | 5 | 5 |
| Antianemic preparations | 5 | 2 | 2 | 5 | 2 |
| Mineral supplements | 2 | 2 | 3 | 3 | 3 |
| Calcium channel blockers | 3 | 0 | 1 | 6 | 3 |
| Drugs used in diabetes | 3 | 2 | 0 | 1 | 6 |
| Beta blocking agents | 1 | 2 | 0 | 5 | 1 |
| Ophthalmologicals | 1 | 1 | 2 | 3 | 1 |
| Urologicals | 1 | 1 | 1 | 3 | 1 |
| Antidiarrheals, intestinal agents (1) | 2 | 2 | 0 | 0 | 3 |
| Antivirals for systemic use | 1 | 3 | 1 | 1 | 0 |
| Corticosteroids for systemic use | 1 | 1 | 0 | 1 | 3 |
| Drugs for constipation | 2 | 0 | 1 | 3 | 1 |
| Anesthetics | 2 | 1 | 0 | 3 | 0 |
| Antiemetics and antinauseants | 2 | 0 | 1 | 1 | 2 |
| Drugs for functional gastrointestinal disorders | 3 | 1 | 0 | 1 | 2 |
| General nutrients | 1 | 1 | 0 | 1 | 2 |
| Topical products for joint and muscular pain | 1 | 2 | 0 | 0 | 2 |
| Antifungals for dermatological use | 0 | 1 | 1 | 0 | 1 |
| Antiobesity preparations, excl. Diet products | 0 | 0 | 0 | 2 | 1 |
| Corticosteroids, dermatological preparations | 1 | 2 | 0 | 1 | 0 |
| Cough and cold preparations | 3 | 1 | 0 | 2 | 0 |
| Other nervous system drugs | 1 | 1 | 0 | 1 | 1 |
| Unspecified herbal and traditional medicine | 1 | 0 | 1 | 1 | 1 |
| All other therapeutic products | 0 | 0 | 0 | 1 | 0 |
| Anti-acne preparations | 0 | 1 | 0 | 1 | 0 |
| Other alimentary tract and metabolism products | 1 | 1 | 0 | 1 | 0 |
| Throat preparations | 0 | 1 | 0 | 0 | 1 |
| Vaccines | 0 | 1 | 0 | 1 | 0 |
| Antiepileptics | 0 | 0 | 1 | 0 | 0 |
| Antihemorrhagics | 0 | 0 | 0 | 0 | 1 |
| Antihypertensives | 0 | 0 | 1 | 0 | 0 |
| Antiprotozoals | 0 | 0 | 0 | 0 | 1 |
| Antipruritics, incl. antihistamines, anesthetics | 0 | 0 | 0 | 0 | 1 |
| Antipsoriatics | 0 | 0 | 0 | 0 | 1 |
| Bile and liver therapy | 0 | 0 | 0 | 1 | 0 |
| Drugs for treatment of bone diseases | 0 | 0 | 1 | 0 | 0 |
| Gynecological antiinfectives and antiseptics | 0 | 0 | 0 | 1 | 0 |
| Immunosuppressants | 0 | 0 | 0 | 1 | 0 |
| Other respiratory system products | 0 | 0 | 0 | 0 | 1 |
| Stomatological preparations | 0 | 0 | 0 | 0 | 1 |
| Tonics | 0 | 0 | 0 | 1 | 0 |
| Muscle relaxants | 2 | 0 | 1 | 1 | 2 |
| Antibiotics,chemotherapeutics (dermatological use) | 1 | 0 | 0 | 1 | 0 |
| Antimycotics for systemic use | 1 | 0 | 0 | 0 | 0 |
Vital signs, including systolic and diastolic blood pressure, pulse rate, temperature, weight, waist circumference, and height, were measured at the time points and recorded in the eCRF. All vital signs were reviewed by the Investigator or delegated physician.
| mmHg | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline | 123.2 ± 10.4 | 124.2 ± 10.1 | 128.9 ± 9.8 | 124.6 ± 10.9 | 124.0 ± 12.9 |
| Week 2: Change from baseline | 0.3 ± 12.5 | -0.2 ± 9.0 | -1.5 ± 12.5 | -2.9 ± 9.3 | -0.8 ± 9.2 |
| Week 4: Change from baseline | 1.7 ± 12.4 | 0.1 ± 11.9 | -3.1 ± 9.4 | -4.7 ± 10.7 | -1.3 ± 10.8 |
| Week 8: Change from baseline | 0.5 ± 10.8 | 0.5 ± 12.5 | -2.1 ± 10.1 | -1.3 ± 10.0 | -3.8 ± 10.5 |
| Week 12: Change from baseline | -0.6 ± 12.2 | -2.1 ± 10.9 | -5.9 ± 11.3 | -1.1 ± 10.2 | -1.3 ± 12.8 |
| Week 16: Change from baseline | 3.8 ± 13.3 | -0.9 ± 11.7 | -6.4 ± 11.1 | -1.4 ± 10.8 | 2.1 ± 9.4 |
Vital signs, including systolic and diastolic blood pressure were measured at the time points and recorded in the eCRF. All vital signs were reviewed by the Investigator or delegated physician.
| mmHg | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline | 80.1 ± 8.0 | 78.7 ± 8.5 | 79.9 ± 9.1 | 78.1 ± 7.6 | 78.7 ± 10.1 |
| Week 2: Change from baseline | -0.7 ± 6.6 | -1.1 ± 8.4 | -0.8 ± 8.7 | -3.1 ± 7.6 | -0.4 ± 7.6 |
| Week 4: Change from baseline | -0.2 ± 7.4 | 1.2 ± 7.8 | -2.1 ± 6.5 | -2.8 ± 9.1 | -2.3 ± 8.0 |
| Week 8: Change from baseline | 0.2 ± 6.7 | -0.5 ± 6.8 | -3.6 ± 6.9 | -0.6 ± 8.4 | -1.6 ± 7.5 |
| Week 12: Change from baseline | -0.5 ± 9.6 | -2.8 ± 9.9 | -2.2 ± 7.1 | -1.8 ± 10.3 | -1.0 ± 9.3 |
| Week 16: Change from baseline | 1.6 ± 7.6 | -1.2 ± 8.3 | -3.8 ± 9.7 | -1.9 ± 9.1 | 0.6 ± 7.2 |
Vital signs, including systolic and diastolic blood pressure, pulse rate, temperature, weight, waist circumference, and height, were measured at the time points and recorded in the eCRF. All vital signs were reviewed by the Investigator or delegated physician.
| beats/min | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline | 69.7 ± 7.8 | 71.4 ± 10.3 | 70.6 ± 8.7 | 70.1 ± 10.2 | 69.7 ± 10.2 |
| Week 2: Change from baseline | -0.1 ± 8.1 | -0.3 ± 7.3 | -0.7 ± 9.9 | -3.1 ± 9.7 | 2.1 ± 9.4 |
| Week 4: Change from baseline | -0.6 ± 6.9 | 0.5 ± 7.6 | -2.8 ± 8.9 | -1.8 ± 6.4 | 0.9 ± 7.7 |
| Week 8: Change from baseline | 0.4 ± 7.7 | -0.5 ± 8.1 | -3.1 ± 9.8 | -2.8 ± 7.9 | 0.3 ± 8.1 |
| Week 12: Change from baseline | 0.1 ± 9.2 | 0.3 ± 8.4 | 0.9 ± 8.8 | -1.4 ± 8.8 | 0.9 ± 7.4 |
| Week 16: Change from baseline | 3.2 ± 10.6 | 3.3 ± 10.5 | 0.0 ± 11.3 | -0.7 ± 8.5 | 0.3 ± 8.4 |
Vital signs, including systolic and diastolic blood pressure, pulse rate, temperature, weight, waist circumference, and height, were measured at the time points and recorded in the eCRF. All vital signs were reviewed by the Investigator or delegated physician.
| Celsius (C) | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline | 36.69 ± 0.43 | 36.62 ± 0.32 | 36.73 ± 0.30 | 36.52 ± 0.46 | 36.68 ± 0.39 |
| Week 2: Change from baseline | -0.09 ± 0.40 | -0.04 ± 0.28 | 0.04 ± 0.26 | 0.12 ± 0.50 | -0.01 ± 0.43 |
| Week 4: Change from baseline | -0.15 ± 0.47 | -0.06 ± 0.34 | 0.01 ± 0.41 | 0.12 ± 0.46 | -0.06 ± 0.32 |
| Week 8: Change from baseline | -0.09 ± 0.38 | -0.01 ± 0.35 | 0.00 ± 0.31 | 0.11 ± 0.49 | -0.01 ± 0.42 |
| Week 12: Change from baseline | -0.12 ± 0.44 | -0.12 ± 0.31 | -0.03 ± 0.38 | 0.04 ± 0.46 | -0.08 ± 0.36 |
| Week 16: Change from baseline | -0.07 ± 0.50 | -0.03 ± 0.30 | -0.04 ± 0.32 | 0.08 ± 0.41 | -0.09 ± 0.41 |
Vital signs, including systolic and diastolic blood pressure, pulse rate, temperature, weight, waist circumference, and height, were measured at the time points and recorded in the eCRF. All vital signs were reviewed by the Investigator or delegated physician.
| Kilogram (Kg) | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline | 75.85 ± 13.13 | 72.65 ± 14.76 | 78.14 ± 15.75 | 72.36 ± 15.26 | 74.11 ± 15.02 |
| Week 2: Change from baseline | 0.20 ± 1.07 | 0.30 ± 1.03 | 0.13 ± 1.32 | -0.13 ± 1.19 | 0.04 ± 0.84 |
| Week 4: Change from baseline | 0.23 ± 1.51 | 0.08 ± 1.11 | 0.12 ± 1.88 | -0.31 ± 1.26 | 0.00 ± 1.35 |
| Week 8: Change from baseline | 0.16 ± 1.98 | 0.26 ± 1.59 | -0.11 ± 1.79 | -0.18 ± 1.78 | -0.25 ± 2.32 |
| Week 12: Change from baseline | -0.02 ± 2.34 | 0.58 ± 2.46 | -0.14 ± 2.03 | -0.08 ± 1.93 | -0.48 ± 2.62 |
| Week 16: Change from baseline | 0.17 ± 2.48 | 0.39 ± 2.81 | -0.13 ± 2.59 | -0.20 ± 2.13 | -0.34 ± 2.82 |
Vital signs, including systolic and diastolic blood pressure, pulse rate, temperature, weight, waist circumference, and height, were measured at the time points and recorded in the eCRF. All vital signs were reviewed by the Investigator or delegated physician.
| kg/m^2 | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline | 28.59 ± 3.81 | 27.69 ± 4.97 | 29.81 ± 4.93 | 27.26 ± 4.85 | 27.72 ± 4.74 |
| Week 2: Change from baseline | 0.07 ± 0.41 | 0.11 ± 0.39 | 0.06 ± 0.5 | -0.04 ± 0.45 | 0.01 ± 0.33 |
| Week 4: Change from baseline | 0.07 ± 0.58 | 0.02 ± 0.42 | 0.06 ± 0.75 | -0.11 ± 0.49 | 0.00 ± 0.53 |
| Week 8: Change from baseline | 0.04 ± 0.75 | 0.09 ± 0.59 | -0.04 ± 0.69 | -0.06 ± 0.66 | -0.09 ± 0.88 |
| Week 12: Change from baseline | -0.03 ± 0.87 | 0.21 ± 0.87 | -0.05 ± 0.79 | -0.02 ± 0.73 | -0.18 ± 0.99 |
| Week 16: Change from baseline | 0.04 ± 0.96 | 0.13 ± 1.01 | -0.04 ± 1.01 | -0.07 ± 0.79 | -0.13 ± 1.07 |
Vital signs, including systolic and diastolic blood pressure, pulse rate, temperature, weight, waist circumference, and height, were measured at the time points and recorded in the eCRF. All vital signs were reviewed by the Investigator or delegated physician.
| cm | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline | 95.47 ± 11.69 | 93.61 ± 13.10 | 97.59 ± 13.15 | 91.12 ± 13.03 | 92.42 ± 12.36 |
| Week 2: Change from baseline | 0.26 ± 3.99 | 0.79 ± 3.55 | -0.91 ± 2.15 | 0.13 ± 3.72 | -0.18 ± 3.90 |
| Week 4: Change from baseline | 0.17 ± 4.99 | -0.07 ± 4.23 | -1.26 ± 3.00 | 0.05 ± 3.84 | -0.09 ± 3.97 |
| Week 8: Change from baseline | -0.14 ± 4.45 | -0.11 ± 4.30 | 0.04 ± 2.77 | -0.76 ± 4.10 | -0.08 ± 4.71 |
| Week 12: Change from baseline | -1.72 ± 5.25 | -1.16 ± 4.87 | 0.60 ± 2.81 | -0.25 ± 3.97 | -0.39 ± 4.42 |
| Week 16: Change from baseline | -0.80 ± 5.46 | -0.99 ± 5.18 | 4.33 ± 12.90 | 0.02 ± 4.58 | -0.24 ± 4.41 |
All ECGs were performed after the subject had rested for 5 minutes in a semi-recumbent position. All ECG reports were reviewed, signed and dated by the Investigator or delegated physician. Reported results are cardiovascular system-examination findings. Normal ECG was decided by investigator. The findings are presented as Normal ECG.
| Participants | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline | 38 | 24 | 11 | 31 | 34 |
| Week 2 | 33 | 23 | 12 | 34 | 27 |
| Week 4 | 32 | 23 | 10 | 28 | 31 |
| Week 8 | 29 | 21 | 12 | 30 | 27 |
| Week 12 | 30 | 22 | 11 | 31 | 31 |
| Week 16 | 27 | 26 | 14 | 31 | 28 |
All ECGs were performed after the subject had rested for 5 minutes in a semi-recumbent position. All ECG reports were reviewed, signed and dated by the Investigator or delegated physician. Reported results are cardiovascular system-examination findings. Abnormal not clinically significant ECG findings were decided by investigator. The findings are presented as Abnormal not clinically significant ECG.
| Participants | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline | 9 | 7 | 6 | 21 | 18 |
| Week 2 | 11 | 8 | 5 | 18 | 24 |
| Week 4 | 13 | 8 | 6 | 23 | 17 |
| Week 8 | 15 | 10 | 5 | 21 | 19 |
| Week 12 | 14 | 8 | 5 | 19 | 14 |
| Week 16 | 16 | 4 | 2 | 20 | 17 |
All ECGs were performed after the subject had rested for 5 minutes in a semi-recumbent position. All ECG reports were reviewed, signed and dated by the Investigator or delegated physician. Reported results are cardiovascular system-examination findings. Abnormal clinically significant ECG findings were decided by investigator. The findings are presented as Abnormal clinically significant ECG.
| Participants | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline | 0 | 0 | 0 | 0 | 0 |
| Week 2 | 0 | 0 | 0 | 0 | 0 |
| Week 4 | 0 | 0 | 1 | 0 | 0 |
| Week 8 | 0 | 0 | 0 | 1 | 0 |
| Week 12 | 0 | 0 | 0 | 0 | 0 |
| Week 16 | 0 | 0 | 0 | 0 | 0 |
All ECGs were performed after the subject had rested for 5 minutes in a semi-recumbent position. The same model of ECG recorder was used throughout the study for any given subject wherever possible. All ECG reports were reviewed, signed and dated by the Investigator or delegated physician. Reports were then filed with the subject's medical record. In categories the number of subjects analyzed (N) for each week is mentioned for each reporting group respectively.
| mSec | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline | 913.5 ± 128.5 | 891.4 ± 145.6 | 934.3 ± 120.3 | 927.8 ± 135.5 | 935.9 ± 151.2 |
| Week 2: Change from baseline | 17.3 ± 84.2 | 23.0 ± 101.7 | -12.6 ± 99.7 | 27.3 ± 94.7 | -2.6 ± 137.7 |
| Week 4: Change from baseline | 1.6 ± 82.8 | 24.8 ± 101.9 | 20.5 ± 108.5 | 27.3 ± 92.6 | 4.5 ± 108.0 |
| Week 8: Change from baseline ) | 35.8 ± 108.7 | 24.8 ± 104.6 | 19.0 ± 128.6 | 22.3 ± 109.2 | -22.6 ± 90.1 |
| Week 12: Change from baseline | 25.5 ± 143.4 | 18.0 ± 110.9 | -23.3 ± 105.1 | 27.2 ± 95.9 | -1.4 ± 107.9 |
| Week 16: Change from baseline | -22.4 ± 135.5 | 2.4 ± 138.5 | -25.4 ± 149.6 | 5.9 ± 110.8 | -8.0 ± 110.3 |
All ECGs were performed after the subject had rested for 5 minutes in a semi-recumbent position. The same model of ECG recorder was used throughout the study for any given subject wherever possible. All ECG reports were reviewed, signed and dated by the Investigator or delegated physician. Reports were then filed with the subject's medical record.
| mSec | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline | 162.6 ± 21.8 | 167.8 ± 16.5 | 162.9 ± 21.7 | 157.2 ± 21.7 | 164.2 ± 25.8 |
| Week 2: Change from baseline | 1.2 ± 9.7 | 4.6 ± 11.7 | 5.2 ± 11.8 | 3.0 ± 10.2 | -2.2 ± 16.3 |
| Week 4: Change from baseline | 0.0 ± 11.2 | 5.9 ± 12.3 | 2.9 ± 12.1 | 3.8 ± 17.7 | 1.8 ± 13.8 |
| Week 8: Change from baseline | 1.5 ± 15.1 | 3.6 ± 10.4 | -0.1 ± 12.3 | 4.3 ± 10.3 | -1.1 ± 14.5 |
| Week 12: Change from baseline | 1.6 ± 11.5 | 3.9 ± 11.7 | 0.7 ± 16.2 | 1.9 ± 11.4 | -1.5 ± 16.9 |
| Week 16: Change from baseline | 0.4 ± 11.3 | 2.2 ± 13.3 | 2.4 ± 16.0 | 2.8 ± 11.1 | -0.4 ± 13.3 |
All ECGs were performed after the subject had rested for 5 minutes in a semi-recumbent position. The same model of ECG recorder was used throughout the study for any given subject wherever possible. All ECG reports were reviewed, signed and dated by the Investigator or delegated physician. Reports were then filed with the subject's medical record.
| mSec | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline | 394.5 ± 31.2 | 397.2 ± 28.7 | 403.5 ± 26.9 | 402.3 ± 40.3 | 401.2 ± 28.0 |
| Week 2: Change from baseline | 3.6 ± 18.0 | 0.2 ± 17.8 | 1.1 ± 21.7 | -0.9 ± 35.6 | -3.2 ± 25.2 |
| Week 4: Change from baseline | 4.7 ± 18.5 | -0.1 ± 18.5 | 4.8 ± 35.2 | 0.2 ± 28.1 | 0.8 ± 21.5 |
| Week 8: Change from baseline | 2.0 ± 19.0 | 1.5 ± 17.2 | 6.5 ± 28.4 | 0.5 ± 34.6 | -4.0 ± 20.3 |
| Week 12: Change from baseline | 1.4 ± 25.1 | 0.8 ± 21.6 | -8.9 ± 20.6 | -1.1 ± 32.9 | 1.0 ± 19.5 |
| Week 16: Change from baseline | -1.7 ± 23.3 | -4.7 ± 24.4 | -3.2 ± 27.6 | -4.1 ± 38.1 | -2.4 ± 25.5 |
All ECGs were performed after the subject had rested for 5 minutes in a semi-recumbent position. The same model of ECG recorder was used throughout the study for any given subject wherever possible. All ECG reports were reviewed, signed and dated by the Investigator or delegated physician. Reports were then filed with the subject's medical record. QTc: QT corrected interval.
| mSec | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline | 410.6 ± 20.9 | 417.9 ± 21.4 | 416.4 ± 14.1 | 415.9 ± 29.3 | 415.2 ± 22.1 |
| Week 2: Change from baseline | 1.6 ± 14.3 | -2.4 ± 11.2 | 2.9 ± 14.7 | -4.9 ± 28.2 | -2.1 ± 15.4 |
| Week 4: Change from baseline | 5.6 ± 16.1 | -5.4 ± 11.8 | 1.7 ± 19.9 | -2.9 ± 24.5 | 0.2 ± 16.3 |
| Week 8: Change from baseline | -3.9 ± 18.5 | -3.8 ± 12.3 | 2.3 ± 10.8 | -2.2 ± 27.5 | 1.2 ± 14.7 |
| Week 12: Change from baseline | -2.4 ± 20.8 | -3.2 ± 14.9 | -3.1 ± 14.4 | -4.7 ± 31.3 | 0.5 ± 14.4 |
| Week 16: Change from baseline | 2.8 ± 14.9 | -4.8 ± 13.6 | 4.3 ± 17.5 | -4.5 ± 31.2 | -1.6 ± 13.6 |
All ECGs were performed after the subject had rested for 5 minutes in a semi-recumbent position. The same model of ECG recorder was used throughout the study for any given subject wherever possible. All ECG reports were reviewed, signed and dated by the Investigator or delegated physician. Reports were then filed with the subject's medical record. QTcF: QT interval with Fridericia's correction.
| mSec | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline | 407.2 ± 20.6 | 413.8 ± 19.9 | 413.2 ± 14.3 | 413.1 ± 30.7 | 411.4 ± 18.6 |
| Week 2: Change from baseline | 1.2 ± 13.7 | -3.5 ± 10.2 | 3.4 ± 13.4 | -4.8 ± 29.5 | -2.5 ± 15.7 |
| Week 4: Change from baseline | 4.8 ± 16.4 | -4.2 ± 11.5 | 2.1 ± 23.4 | -3.5 ± 24.7 | 0.4 ± 15.4 |
| Week 8: Change from baseline | -2.8 ± 15.9 | -2.7 ± 10.9 | 4.0 ± 13.2 | -2.6 ± 28.7 | -0.4 ± 16.1 |
| Week 12: Change from baseline | -1.7 ± 18.5 | -1.9 ± 13.9 | -5.1 ± 13.2 | -5.1 ± 30.8 | 1.1 ± 14.6 |
| Week 16: Change from baseline | 2.6 ± 15.1 | -5.6 ± 14.2 | 1.5 ± 14.5 | -4.8 ± 32.7 | -1.3 ± 16.4 |
Absolute QTcF values reported.
| Participants | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline: missing | 0 | 0 | 0 | 0 | 0 |
| Baseline: <=450 msec | 46 | 30 | 16 | 51 | 50 |
| Baseline: >450 to <=480 msec | 1 | 1 | 1 | 0 | 2 |
| Baseline: >480 to <=500 msec | 0 | 0 | 0 | 0 | 0 |
| Baseline: >500 msec | 0 | 0 | 0 | 1 | 0 |
| Week 2: missing | 3 | 0 | 0 | 0 | 1 |
| Week 2: <=450 msec | 44 | 30 | 16 | 52 | 50 |
| Week 2: >450 to <=480 msec | 0 | 1 | 1 | 0 | 1 |
| Week 2: >480 to <=500 msec | 0 | 0 | 0 | 0 | 0 |
| Week 2: >500 msec | 0 | 0 | 0 | 0 | 0 |
| Week 4: missing | 2 | 0 | 0 | 1 | 4 |
| Week 4: <=450 msec | 44 | 30 | 16 | 51 | 47 |
| Week 4: >450 to <=480 msec | 1 | 1 | 0 | 0 | 1 |
| Week 4: >480 to <=500 msec | 0 | 0 | 0 | 0 | 0 |
| Week 4: >500 msec | 0 | 0 | 1 | 0 | 0 |
| Week 8: missing | 3 | 0 | 0 | 0 | 6 |
| Week 8: <=450 msec | 44 | 30 | 17 | 52 | 46 |
| Week 8: >450 to <=480 msec | 0 | 1 | 0 | 0 | 0 |
| Week 8: >480 to <=500 msec | 0 | 0 | 0 | 0 | 0 |
| Week 8: >500 msec | 0 | 0 | 0 | 0 | 0 |
| Week 12: missing | 3 | 1 | 1 | 2 | 7 |
| Week 12: <=450 msec | 44 | 30 | 16 | 50 | 45 |
| Week 12: >450 to <=480 msec | 0 | 0 | 0 | 0 | 0 |
| Week 12: >480 to <=500 msec | 0 | 0 | 0 | 0 | 0 |
| Week 12: >500 msec | 0 | 0 | 0 | 0 | 0 |
| Week 16: missing | 4 | 1 | 1 | 1 | 7 |
| Week 16: <=450 msec | 42 | 30 | 15 | 51 | 44 |
| Week 16: >450 to <=480 msec | 1 | 0 | 1 | 0 | 1 |
| Week 16: >480 to <=500 msec | 0 | 0 | 0 | 0 | 0 |
| Week 16: >500 msec | 0 | 0 | 0 | 0 | 0 |
Increase from Baseline overtime was reported.
| Participants | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Week 2: missing | 3 | 0 | 0 | 0 | 1 |
| Week 2: <=0 msec | 19 | 21 | 8 | 27 | 29 |
| Week 2: >0 to <=30 msec | 25 | 10 | 8 | 24 | 22 |
| Week 2: >30 to <=60 msec | 0 | 0 | 1 | 1 | 0 |
| Week 2: >60 msec | 0 | 0 | 0 | 0 | 0 |
| Week 4: missing | 2 | 0 | 0 | 1 | 4 |
| Week 4: <=0 msec | 20 | 20 | 8 | 27 | 24 |
| Week 4: >0 to <=30 msec | 23 | 11 | 8 | 24 | 22 |
| Week 4: >30 to <=60 msec | 2 | 0 | 0 | 0 | 2 |
| Week 4: >60 msec | 0 | 0 | 1 | 0 | 0 |
| Week 8: missing | 3 | 0 | 0 | 0 | 6 |
| Week 8: <=0 msec | 24 | 20 | 8 | 25 | 19 |
| Week 8: >0 to <=30 msec | 20 | 11 | 9 | 26 | 26 |
| Week 8: >30 to <=60 msec | 0 | 0 | 0 | 1 | 1 |
| Week 8: >60 msec | 0 | 0 | 0 | 0 | 0 |
| Week 12: missing | 3 | 1 | 1 | 2 | 7 |
| Week 12: <=0 msec | 24 | 15 | 10 | 29 | 22 |
| Week 12: >0 to <=30 msec | 19 | 15 | 6 | 21 | 22 |
| Week 12: >30 to <=60 msec | 1 | 0 | 0 | 0 | 1 |
| Week 12: >60 msec | 0 | 0 | 0 | 0 | 0 |
| Week 16: missing | 4 | 1 | 1 | 1 | 7 |
| Week 16: <=0 msec | 18 | 18 | 7 | 26 | 24 |
| Week 16: >0 to <=30 msec | 23 | 12 | 9 | 24 | 20 |
| Week 16: >30 to <=60 msec | 2 | 0 | 0 | 1 | 1 |
| Week 16: >60 msec | 0 | 0 | 0 | 0 | 0 |
The Columbia Suicide Severity Rating Scale (C-SSRS) is a rating scale created to evaluate suicidality in adults and children over the age of 12. It rates an individual's degree of suicidal ideation on a scale, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent." The version used was the eC-SSRS, which is a subject-reported version of the scale. Shifts from baseline versus post-baseline to demonstrate changes in categories (cat) were reported using cat 1 (No Suicidal Ideation or Behaviour), cat 2 (Suicidal Ideation) and cat 3 (Suicidal Behaviour).
| Participants | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Week 4: shift from cat 1 to cat 1 | 34 | 14 | 13 | 38 | 38 |
| Week 4: shift from cat 1 to cat 2 | 1 | 0 | 0 | 0 | 0 |
| Week 4: shift from cat 1 to cat 3 | 0 | 0 | 0 | 0 | 0 |
| Week 4: shift from cat 2 to cat 1 | 5 | 7 | 2 | 4 | 7 |
| Week 4: shift from cat 2 to cat 2 | 1 | 0 | 0 | 0 | 0 |
| Week 4: shift from cat 2 to cat 3 | 0 | 0 | 0 | 0 | 0 |
| Week 4: shift from cat 3 to cat 1 | 1 | 5 | 1 | 2 | 1 |
| Week 4: shift from cat 3 to cat 2 | 0 | 0 | 0 | 0 | 0 |
| Week 4: shift from cat 3 to cat 3 | 0 | 0 | 0 | 0 | 0 |
| Week 12: shift from cat 1 to cat 1 | 34 | 14 | 12 | 40 | 33 |
| Week 12: shift from cat 1 to cat 2 | 0 | 0 | 0 | 0 | 0 |
| Week 12: shift from cat 1 to cat 3 | 0 | 0 | 0 | 0 | 0 |
| Week 12: shift from cat 2 to cat 1 | 7 | 5 | 3 | 2 | 7 |
| Week 12: shift from cat 2 to cat 2 | 0 | 2 | 0 | 1 | 0 |
| Week 12: shift from cat 2 to cat 3 | 0 | 0 | 0 | 0 | 0 |
| Week 12: shift from cat 3 to cat 1 | 1 | 5 | 1 | 2 | 1 |
| Week 12: shift from cat 3 to cat 2 | 0 | 0 | 0 | 0 | 0 |
| Week 12: shift from cat 3 to cat 3 | 0 | 0 | 0 | 0 | 0 |
| Week 16: shift from cat 1 to cat 1 | 33 | 15 | 12 | 40 | 33 |
| Week 16: shift from cat 1 to cat 2 | 0 | 0 | 0 | 0 | 0 |
| Week 16: shift from cat 1 to cat 3 | 0 | 0 | 0 | 0 | 0 |
| Week 16: shift from cat 2 to cat 1 | 6 | 6 | 3 | 4 | 7 |
| Week 16: shift from cat 2 to cat 2 | 1 | 1 | 0 | 0 | 0 |
| Week 16: shift from cat 2 to cat 3 | 0 | 0 | 0 | 0 | 0 |
| Week 16: shift from cat 3 to cat 1 | 1 | 5 | 1 | 2 | 1 |
| Week 16: shift from cat 3 to cat 2 | 0 | 0 | 0 | 0 | 0 |
| Week 16: shift from cat 3 to cat 3 | 0 | 0 | 0 | 0 | 0 |
Blood samples for clinical hematology assessment were collected and sent to the central laboratory for analysis.
| 10^12*cells/L | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline | 4.568 ± 0.392 | 4.537 ± 0.375 | 4.510 ± 0.365 | 4.516 ± 0.429 | 4.563 ± 0.406 |
| Week 2: Change from baseline | -0.106 ± 0.262 | -0.108 ± 0.218 | 0.007 ± 0.254 | -0.095 ± 0.215 | -0.090 ± 0.210 |
| Week 4: Change from baseline | -0.094 ± 0.278 | -0.083 ± 0.217 | 0.072 ± 0.200 | -0.087 ± 0.203 | -0.077 ± 0.229 |
| Week 12: Change from baseline | -0.057 ± 0.277 | -0.085 ± 0.256 | 0.039 ± 0.273 | -0.057 ± 0.265 | -0.057 ± 0.202 |
| Week 16: Change from baseline | -0.060 ± 0.293 | -0.023 ± 0.250 | -0.033 ± 0.290 | -0.085 ± 0.254 | -0.040 ± 0.240 |
Blood samples for clinical hematology assessment were collected and sent to the central laboratory for analysis.
| Volume proportion | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline | 0.4230 ± 0.0347 | 0.4184 ± 0.0303 | 0.4102 ± 0.0384 | 0.4088 ± 0.0312 | 0.4182 ± 0.0346 |
| Week 2: Change from baseline | -0.0121 ± 0.0261 | -0.0079 ± 0.0220 | 0.0016 ± 0.0211 | -0.0079 ± 0.0195 | -0.0138 ± 0.0199 |
| Week 4: Change from baseline | -0.0097 ± 0.0249 | -0.0060 ± 0.0194 | 0.0075 ± 0.0144 | -0.0080 ± 0.0186 | -0.0100 ± 0.0234 |
| Week 12: Change from baseline | -0.0106 ± 0.0294 | -0.0036 ± 0.0220 | 0.0087 ± 0.0276 | -0.0083 ± 0.0258 | -0.0115 ± 0.0231 |
| Week 16: Change from baseline | -0.0140 ± 0.0258 | -0.0006 ± 0.0250 | 0.0015 ± 0.0244 | -0.0100 ± 0.0235 | -0.0099 ± 0.0274 |
Blood samples for clinical hematology assessment were collected and sent to the central laboratory for analysis.
| g/L | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline | 138.4 ± 10.9 | 137.3 ± 10.0 | 136.4 ± 11.6 | 134.6 ± 9.8 | 135.6 ± 11.4 |
| Week 2: Change from baseline | -3.0 ± 7.8 | -3.0 ± 6.6 | -0.2 ± 7.5 | -2.8 ± 6.3 | -2.5 ± 5.4 |
| Week 4: Change from baseline | -2.7 ± 8.1 | -2.6 ± 6.7 | 2.6 ± 5.3 | -2.8 ± 5.7 | -2.4 ± 6.2 |
| Week 12: Change from baseline | -2.1 ± 7.7 | -2.5 ± 7.5 | 0.8 ± 7.5 | -2.3 ± 7.1 | -1.5 ± 5.9 |
| Week 16: Change from baseline | -1.9 ± 8.5 | -0.7 ± 6.9 | -1.7 ± 8.2 | -2.6 ± 6.9 | -1.1 ± 6.4 |
Blood samples for clinical hematology assessment were collected and sent to the central laboratory for analysis.
| fL | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline | 92.74 ± 4.65 | 92.39 ± 4.51 | 90.92 ± 3.00 | 90.82 ± 5.25 | 91.88 ± 5.69 |
| Week 2: Change from baseline | -0.56 ± 2.35 | 0.51 ± 2.58 | 0.24 ± 2.02 | 0.10 ± 1.72 | -1.29 ± 3.35 |
| Week 4: Change from baseline | -0.22 ± 2.53 | 0.49 ± 2.31 | 0.27 ± 2.85 | -0.10 ± 1.92 | -0.73 ± 4.48 |
| Week 12: Change from baseline | -1.22 ± 3.30 | 0.98 ± 3.41 | 1.18 ± 2.72 | -0.77 ± 2.66 | -1.47 ± 4.49 |
| Week 16: Change from baseline | -1.91 ± 2.99 | 0.36 ± 3.41 | 1.05 ± 2.39 | -0.55 ± 4.13 | -1.42 ± 5.06 |
Blood samples for clinical hematology assessment were collected and sent to the central laboratory for analysis.
| 10^9*cells/L | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline (Leukocytes) | 6.09 ± 1.80 | 6.17 ± 1.89 | 6.32 ± 1.35 | 6.31 ± 1.74 | 6.40 ± 1.76 |
| Week 2: Change from baseline (Leukocytes) | -0.19 ± 1.02 | -0.24 ± 0.99 | -0.13 ± 0.97 | -0.25 ± 1.33 | -0.12 ± 1.44 |
| Week 4: Change from baseline (Leukocytes) | 0.41 ± 2.80 | -0.09 ± 0.96 | 0.16 ± 1.02 | -0.27 ± 1.44 | -0.20 ± 1.04 |
| Week 12: Change from baseline (Leukocytes) | -0.12 ± 1.28 | -0.11 ± 1.07 | 0.08 ± 1.98 | -0.29 ± 1.55 | -0.08 ± 1.59 |
| Week 16: Change from baseline (Leukocytes) | -0.20 ± 1.15 | 0.19 ± 1.84 | -0.05 ± 1.20 | -0.12 ± 1.88 | 0.09 ± 1.18 |
| Baseline (Platelets) | 273.6 ± 53.7 | 270.8 ± 66.2 | 254.9 ± 37.2 | 280.6 ± 62.8 | 277.0 ± 59.3 |
| Week 2: Change from baseline (Platelets) | 0.6 ± 36.2 | -3.9 ± 31.8 | -6.0 ± 22.4 | -5.5 ± 32.4 | -3.0 ± 30.7 |
| Week 4: Change from baseline (Platelets) | 9.5 ± 43.7 | -2.1 ± 27.6 | 7.6 ± 35.8 | -5.7 ± 29.9 | -1.4 ± 34.4 |
| Week 12: Change from baseline (Platelets) | 8.2 ± 54.7 | -0.5 ± 33.1 | 14.7 ± 23.9 | 0.0 ± 30.6 | 1.3 ± 45.7 |
| Week16: Change from baseline (Platelets) | 12.4 ± 28.6 | 5.7 ± 37.3 | 3.9 ± 28.7 | 1.2 ± 32.9 | 9.5 ± 38.0 |
| Baseline (Basophils) | 0.03 ± 0.04 | 0.05 ± 0.05 | 0.04 ± 0.05 | 0.03 ± 0.05 | 0.03 ± 0.04 |
| Week 2: Change from baseline (Basophils) | 0.00 ± 0.04 | 0.00 ± 0.02 | -0.02 ± 0.04 | 0.00 ± 0.04 | 0.01 ± 0.04 |
| Week 4: Change from baseline (Basophils) | 0.00 ± 0.05 | -0.01 ± 0.03 | -0.02 ± 0.04 | -0.01 ± 0.04 | 0.01 ± 0.05 |
| Week 12: Change from baseline (Basophils) | 0.00 ± 0.04 | -0.01 ± 0.04 | -0.02 ± 0.06 | 0.00 ± 0.05 | 0.00 ± 0.03 |
| Week 16: Change from baseline (Basophils) | 0.00 ± 0.04 | 0.00 ± 0.00 | 0.00 ± 0.05 | -0.01 ± 0.04 | 0.01 ± 0.05 |
| Baseline (Eosinophils) | 0.14 ± 0.09 | 0.19 ± 0.12 | 0.18 ± 0.15 | 0.20 ± 0.24 | 0.18 ± 0.14 |
| Week 2: Change from baseline (Eosinophils) | 0.00 ± 0.06 | 0.00 ± 0.09 | -0.01 ± 0.07 | -0.03 ± 0.12 | -0.02 ± 0.09 |
| Week 4: Change from baseline (Eosinophils) | -0.01 ± 0.09 | -0.01 ± 0.08 | -0.01 ± 0.11 | -0.03 ± 0.16 | -0.02 ± 0.07 |
| Week 12: Change from baseline (Eosinophils) | 0.02 ± 0.09 | 0.02 ± 0.09 | 0.00 ± 0.11 | -0.05 ± 0.19 | -0.03 ± 0.09 |
| Week 16: Change from baseline (Eosinophils) | 0.00 ± 0.10 | -0.02 ± 0.08 | -0.01 ± 0.13 | -0.05 ± 0.17 | -0.02 ± 0.11 |
| Baseline (Lymphocytes) | 1.98 ± 0.67 | 1.90 ± 0.63 | 1.78 ± 0.50 | 2.11 ± 0.66 | 2.00 ± 0.62 |
| Week 2: Change from baseline (Lymphocytes) | -0.06 ± 0.34 | -0.11 ± 0.33 | -0.10 ± 0.31 | -0.11 ± 0.41 | -0.14 ± 0.39 |
| Week 4: Change from baseline (Lymphocytes) | -0.08 ± 0.38 | -0.13 ± 0.34 | 0.04 ± 0.45 | -0.08 ± 0.50 | -0.02 ± 0.38 |
| Week 12: Change from baseline (Lymphocytes) | -0.05 ± 0.36 | -0.08 ± 0.34 | -0.07 ± 0.24 | -0.09 ± 0.47 | -0.05 ± 0.29 |
| Week 16: Change from baseline (Lymphocytes) | -0.14 ± 0.46 | -0.11 ± 0.40 | -0.07 ± 0.32 | -0.13 ± 0.39 | 0.01 ± 0.36 |
| Baseline (Monocytes) | 0.44 ± 0.13 | 0.47 ± 0.14 | 0.51 ± 0.10 | 0.47 ± 0.14 | 0.46 ± 0.17 |
| Week 2: Change from baseline (Monocytes) | 0.00 ± 0.09 | -0.02 ± 0.13 | -0.02 ± 0.13 | -0.05 ± 0.14 | -0.01 ± 0.11 |
| Week 4: Change from baseline (Monocytes) | 0.02 ± 0.09 | -0.03 ± 0.10 | 0.01 ± 0.12 | -0.03 ± 0.11 | -0.02 ± 0.12 |
| Week 12: Change from baseline (Monocytes) | 0.01 ± 0.11 | -0.03 ± 0.10 | -0.06 ± 0.11 | -0.03 ± 0.13 | 0.00 ± 0.15 |
| Week 16: Change from baseline (Monocytes) | 0.01 ± 0.11 | -0.02 ± 0.14 | -0.03 ± 0.13 | 0.00 ± 0.13 | 0.00 ± 0.14 |
| Baseline (Neutrophils) | 3.50 ± 1.34 | 3.59 ± 1.33 | 3.81 ± 1.13 | 3.51 ± 1.41 | 3.73 ± 1.28 |
| Week 2: Change from baseline (Neutrophils) | -0.14 ± 0.79 | -0.15 ± 0.84 | 0.03 ± 0.80 | -0.08 ± 1.24 | 0.01 ± 1.32 |
| Week 4: Change from baseline (Neutrophils) | 0.11 ± 1.04 | 0.09 ± 0.86 | 0.14 ± 0.70 | -0.13 ± 1.24 | -0.16 ± 0.91 |
| Week 12: Change from baseline (Neutrophils) | -0.11 ± 1.16 | -0.02 ± 0.97 | 0.22 ± 1.79 | -0.13 ± 1.26 | -0.01 ± 1.39 |
| Week 16: Change from baseline (Neutrophils) | -0.08 ± 1.19 | 0.33 ± 1.70 | 0.05 ± 0.96 | 0.04 ± 1.73 | 0.10 ± 0.95 |
Blood samples for clinical hematology assessment were collected and sent to the central laboratory for analysis.
| Percentage of total white blood cells | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline (Basophils/ Leukocytes) | 0.61 ± 0.36 | 0.72 ± 0.34 | 0.59 ± 0.26 | 0.69 ± 0.47 | 0.59 ± 0.31 |
| Week 2: Change from baseline (Basophils/ Leukocytes) | 0.02 ± 0.22 | -0.01 ± 0.19 | -0.01 ± 0.18 | -0.04 ± 0.30 | 0.07 ± 0.20 |
| Week 4: Change from baseline (Basophils/ Leukocytes) | 0.03 ± 0.28 | -0.04 ± 0.21 | -0.02 ± 0.22 | -0.06 ± 0.31 | 0.08 ± 0.30 |
| Week 12: Change from baseline (Basophils/ Leukocytes) | 0.02 ± 0.35 | 0.01 ± 0.26 | 0.03 ± 0.15 | -0.07 ± 0.31 | 0.05 ± 0.21 |
| Week 16: Change from baseline (Basophils/ Leukocytes) | 0.00 ± 0.27 | 0.05 ± 0.20 | 0.06 ± 0.22 | -0.05 ± 0.32 | 0.01 ± 0.19 |
| Baseline (Eosinophils/ Leukocytes) | 2.17 ± 1.22 | 2.89 ± 1.67 | 2.66 ± 1.80 | 2.97 ± 3.43 | 2.76 ± 1.78 |
| Week 2: Change from baseline (Eosinophils/ Leukocytes) | 0.16 ± 0.87 | 0.20 ± 1.01 | -0.12 ± 0.75 | -0.24 ± 1.78 | -0.13 ± 1.17 |
| Week 4: Change from baseline (Eosinophils/ Leukocytes) | -0.13 ± 0.84 | -0.06 ± 0.99 | -0.15 ± 1.14 | -0.43 ± 2.43 | -0.17 ± 0.99 |
| Week 12: Change from baseline (Eosinophils/ Leukocytes) | 0.33 ± 1.22 | 0.41 ± 1.49 | 0.11 ± 1.16 | -0.53 ± 2.58 | -0.27 ± 1.43 |
| Week16: Change from baseline (Eosinophils/ Leukocytes) | 0.10 ± 1.59 | -0.15 ± 1.18 | 0.00 ± 1.53 | -0.42 ± 2.33 | -0.32 ± 1.57 |
| Baseline (Lymphocytes/ Leukocytes) | 32.87 ± 7.02 | 31.31 ± 6.31 | 28.71 ± 7.07 | 34.20 ± 9.42 | 31.95 ± 7.49 |
| Week 2: Change from baseline (Lymphocytes/ Leukocytes) | 0.27 ± 5.12 | -0.54 ± 5.60 | -1.32 ± 4.45 | -0.83 ± 7.48 | -1.37 ± 6.02 |
| Week 4: Change from baseline (Lymphocytes/ Leukocytes) | -1.24 ± 5.98 | -1.25 ± 5.12 | -0.89 ± 3.68 | -0.43 ± 7.03 | 0.68 ± 4.85 |
| Week 12: Change from baseline (Lymphocytes/ Leukocytes) | -0.32 ± 6.82 | -0.51 ± 6.59 | 0.13 ± 4.78 | -0.41 ± 6.56 | -0.07 ± 4.94 |
| Week 16: Change from baseline (Lymphocytes/ Leukocytes) | -0.89 ± 7.90 | -1.40 ± 8.07 | -0.75 ± 4.70 | -0.95 ± 7.10 | -0.70 ± 4.39 |
| Baseline (Monocytes/Leukocytes) | 7.41 ± 1.76 | 7.71 ± 2.07 | 8.18 ± 1.62 | 7.55 ± 1.67 | 7.15 ± 1.67 |
| Week 2: Change from baseline (Monocytes/Leukocytes) | 0.19 ± 1.11 | 0.05 ± 1.83 | -0.24 ± 2.01 | -0.36 ± 1.59 | 0.08 ± 1.20 |
| Week 4: Change from baseline (Monocytes/Leukocytes) | 0.24 ± 1.31 | -0.19 ± 1.24 | -0.29 ± 1.71 | -0.13 ± 1.25 | 0.21 ± 1.81 |
| Week 12: Change from baseline (Monocytes/Leukocytes) | 0.45 ± 1.34 | -0.19 ± 1.64 | -0.67 ± 1.27 | -0.01 ± 1.57 | 0.24 ± 1.52 |
| Week 16: Change from baseline (Monocytes/Leukocytes) | 0.48 ± 1.67 | -0.50 ± 1.75 | -0.48 ± 1.45 | 0.27 ± 1.67 | 0.08 ± 1.68 |
| Baseline (Neutrophils/Leukocytes) | 56.93 ± 8.12 | 57.37 ± 7.13 | 59.85 ± 8.07 | 54.59 ± 0.43 | 57.56 ± 8.01 |
| Week 2: Change from baseline (Neutrophils/Leukocytes) | -0.64 ± 6.11 | 0.29 ± 6.64 | 1.70 ± 5.11 | 1.47 ± 8.32 | 1.36 ± 6.75 |
| Week 4: Change from baseline (Neutrophils/Leukocytes) | 1.10 ± 6.92 | 1.54 ± 5.78 | 1.35 ± 4.76 | 1.05 ± 8.38 | -0.80 ± 6.01 |
| Week 12: Change from baseline (Neutrophils/Leukocytes) | -0.48 ± 7.92 | 0.27 ± 7.61 | 0.40 ± 5.40 | 1.01 ± 7.54 | 0.05 ± 5.60 |
| Week 16: Change from baseline (Neutrophils/Leukocytes) | 0.30 ± 9.57 | 2.00 ± 9.27 | 1.17 ± 5.31 | 1.14 ± 8.14 | 0.94 ± 5.30 |
Blood samples for clinical chemistry assessment were collected and sent to the central laboratory for analysis.
| mmol/L | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline (Sodium) | 141.3 ± 2.0 | 141.6 ± 2.4 | 141.6 ± 2.9 | 141.2 ± 1.8 | 141.3 ± 2.0 |
| Week 2: Change from baseline (Sodium) | -0.1 ± 1.9 | 0.1 ± 2.1 | -0.6 ± 2.0 | -0.5 ± 1.8 | -0.5 ± 1.7 |
| Week 4: Change from baseline (Sodium) | -0.5 ± 1.7 | -0.2 ± 2.1 | -0.9 ± 2.4 | -0.3 ± 1.8 | 0.0 ± 1.6 |
| Week 8: Change from baseline (Sodium) | 0.0 ± 1.8 | -0.8 ± 2.5 | -0.6 ± 1.6 | 0.1 ± 2.0 | 0.1 ± 1.7 |
| Week 12: Change from baseline (Sodium) | -0.5 ± 1.9 | -0.6 ± 2.5 | -0.9 ± 1.7 | 0.0 ± 2.2 | -0.1 ± 1.8 |
| Week 16: Change from baseline (Sodium) | -0.2 ± 1.7 | -0.1 ± 2.1 | -0.1 ± 2.0 | -0.2 ± 2.0 | -0.3 ± 1.8 |
| Baseline (Potassium) | 4.51 ± 0.38 | 4.43 ± 0.30 | 4.23 ± 0.33 | 4.37 ± 0.44 | 4.36 ± 0.45 |
| Week 2: Change from baseline (Potassium) | -0.02 ± 0.35 | -0.08 ± 0.36 | 0.06 ± 0.35 | 0.01 ± 0.44 | -0.07 ± 0.40 |
| Week 4: Change from baseline (Potassium) | -0.04 ± 0.39 | -0.09 ± 0.40 | 0.06 ± 0.27 | -0.02 ± 0.45 | -0.13 ± 0.31 |
| Week 8: Change from baseline (Potassium) | 0.06 ± 0.39 | -0.10 ± 0.34 | -0.05 ± 0.30 | 0.02 ± 0.51 | -0.11 ± 0.42 |
| Week 12: Change from baseline (Potassium) | -0.10 ± 0.40 | -0.07 ± 0.34 | 0.10 ± 0.41 | 0.03 ± 0.51 | -0.16 ± 0.40 |
| Week 16: Change from baseline (Potassium) | -0.13 ± 0.39 | -0.10 ± 0.33 | -0.04 ± 0.33 | 0.04 ± 0.45 | -0.16 ± 0.40 |
| Baseline (Glucose) | 5.06 ± 0.83 | 5.32 ± 1.11 | 5.16 ± 0.71 | 5.04 ± 0.74 | 5.81 ± 2.70 |
| Week 2: Change from baseline (Glucose) | 0.22 ± 1.12 | -0.07 ± 0.92 | 0.04 ± 1.01 | 0.28 ± 0.97 | 0.21 ± 1.89 |
| Week 4: Change from baseline (Glucose) | 0.24 ± 0.73 | 0.02 ± 0.87 | -0.24 ± 1.08 | 0.02 ± 0.87 | -0.29 ± 2.39 |
| Week 8: Change from baseline (Glucose) | 0.12 ± 0.54 | -0.15 ± 1.15 | -0.13 ± 1.17 | 0.01 ± 1.09 | -0.12 ± 1.35 |
| Week 12: Change from baseline (Glucose) | -0.06 ± 0.94 | -0.09 ± 1.06 | 0.13 ± 0.55 | 0.21 ± 1.48 | -0.34 ± 1.82 |
| Week 16: Change from baseline (Glucose) | 0.14 ± 0.81 | 0.06 ± 1.03 | 0.10 ± 0.94 | 0.09 ± 1.02 | -0.43 ± 1.58 |
| Baseline (Urea Nitrogen) | 5.74 ± 1.49 | 5.64 ± 1.54 | 5.70 ± 1.45 | 5.34 ± 1.51 | 5.31 ± 1.26 |
| Week 2: Change from baseline (Urea Nitrogen) | -0.43 ± 1.05 | 0.04 ± 1.21 | 0.50 ± 1.35 | 0.50 ± 1.25 | 0.24 ± 1.15 |
| Week 4: Change from baseline (Urea Nitrogen) | -0.30 ± 1.58 | 0.12 ± 0.95 | 0.17 ± 1.25 | 0.36 ± 1.42 | 0.12 ± 1.22 |
| Week 8: Change from baseline (Urea Nitrogen) | -0.23 ± 1.10 | -0.34 ± 1.18 | 0.13 ± 1.71 | 0.53 ± 1.58 | -0.03 ± 1.34 |
| Week 12: Change from baseline (Urea Nitrogen) | -0.21 ± 1.20 | -0.17 ± 1.13 | 0.45 ± 2.11 | 0.31 ± 1.09 | -0.10 ± 1.31 |
| Week 16: Change from baseline (Urea Nitrogen) | -0.24 ± 1.41 | -0.19 ± 1.32 | -0.03 ± 1.57 | 0.24 ± 1.11 | -0.01 ± 1.25 |
| Baseline (Calcium) | 2.348 ± 0.082 | 2.354 ± 0.093 | 2.325 ± 0.091 | 2.347 ± 0.117 | 2.342 ± 0.091 |
| Week 2: Change from baseline (Calcium) | -0.046 ± 0.081 | -0.052 ± 0.082 | 0.011 ± 0.102 | -0.019 ± 0.079 | -0.050 ± 0.101 |
| Week 4: Change from baseline (Calcium) | -0.035 ± 0.094 | -0.035 ± 0.077 | 0.028 ± 0.068 | -0.018 ± 0.099 | -0.036 ± 0.094 |
| Week 8: Change from baseline (Calcium) | -0.008 ± 0.109 | -0.034 ± 0.085 | 0.002 ± 0.091 | -0.021 ± 0.108 | -0.042 ± 0.077 |
| Week 12: Change from baseline (Calcium) | -0.006 ± 0.088 | -0.018 ± 0.091 | 0.014 ± 0.108 | -0.014 ± 0.097 | -0.042 ± 0.084 |
| Week 16 Change from baseline (Calcium) | -0.005 ± 0.090 | -0.033 ± 0.093 | 0.003 ± 0.097 | -0.009 ± 0.100 | -0.027 ± 0.104 |
| Baseline (Phosphate) | 1.28 ± 0.15 | 1.28 ± 0.15 | 1.17 ± 0.15 | 1.26 ± 0.16 | 1.22 ± 0.15 |
| Week 2: Change from baseline (Phosphate) | -0.02 ± 0.13 | 0.00 ± 0.13 | 0.03 ± 0.15 | 0.00 ± 0.15 | -0.02 ± 0.17 |
| Week 4: Change from baseline (Phosphate) | 0.00 ± 0.14 | 0.00 ± 0.16 | 0.05 ± 0.09 | -0.01 ± 0.15 | -0.03 ± 0.15 |
| Week 8: Change from baseline (Phosphate) | -0.01 ± 0.13 | -0.02 ± 0.15 | 0.07 ± 0.11 | 0.02 ± 0.18 | -0.02 ± 0.14 |
| Week 12: Change from baseline (Phosphate) | -0.02 ± 0.16 | -0.02 ± 0.17 | 0.06 ± 0.15 | 0.02 ± 0.19 | -0.06 ± 0.14 |
| Week 16: Change from baseline (Phosphate) | -0.02 ± 0.17 | -0.01 ± 0.16 | 0.00 ± 0.14 | -0.01 ± 0.17 | -0.01 ± 0.13 |
| Baseline (Bicarbonate) | 25.5 ± 2.4 | 26.6 ± 3.4 | 26.2 ± 3.7 | 26.7 ± 2.7 | 26.0 ± 2.9 |
| Week 2: Change from baseline (Bicarbonate) | 0.3 ± 1.7 | 0.0 ± 2.0 | -0.6 ± 2.3 | -0.5 ± 2.1 | -0.2 ± 2.0 |
| Week 4: Change from baseline (Bicarbonate) | 0.2 ± 2.0 | -0.1 ± 2.0 | -0.1 ± 2.3 | -0.4 ± 2.1 | 0.0 ± 1.7 |
| Week 8: Change from baseline (Bicarbonate) | 0.3 ± 1.8 | 0.0 ± 2.3 | -0.2 ± 2.1 | -0.6 ± 1.9 | 0.3 ± 1.9 |
| Week 12: Change from baseline (Bicarbonate) | 0.6 ± 2.1 | -0.4 ± 2.1 | -0.5 ± 2.4 | -0.6 ± 1.9 | -0.2 ± 1.9 |
| Week 16: Change from baseline (Bicarbonate) | 0.4 ± 1.5 | -0.1 ± 2.3 | -0.5 ± 2.7 | -0.3 ± 2.3 | -0.1 ± 2.1 |
| Baseline (Magnesium) | 0.809 ± 0.075 | 0.833 ± 0.084 | 0.826 ± 0.075 | 0.821 ± 0.067 | 0.817 ± 0.076 |
| Week 2: Change from baseline (Magnesium) | -0.011 ± 0.066 | -0.027 ± 0.070 | -0.009 ± 0.065 | -0.013 ± 0.066 | -0.037 ± 0.057 |
| Week 4: Change from baseline (Magnesium) | -0.008 ± 0.054 | -0.035 ± 0.057 | 0.002 ± 0.052 | -0.017 ± 0.061 | -0.017 ± 0.060 |
| Week 8: Change from baseline (Magnesium) | 0.005 ± 0.056 | -0.016 ± 0.065 | 0.010 ± 0.048 | 0.005 ± 0.077 | -0.008 ± 0.063 |
| Week 12: Change from baseline (Magnesium) | -0.033 ± 0.059 | -0.025 ± 0.060 | -0.035 ± 0.058 | -0.012 ± 0.070 | -0.016 ± 0.059 |
| Week 16: Change from baseline (Magnesium) | -0.024 ± 0.052 | -0.043 ± 0.069 | -0.022 ± 0.063 | -0.025 ± 0.057 | -0.022 ± 0.052 |
| Baseline (Chloride) | 105.6 ± 2.2 | 105.4 ± 2.1 | 105.5 ± 2.4 | 104.8 ± 2.4 | 105.3 ± 2.6 |
| Week 2: Change from baseline (Chloride) | 0.2 ± 2.0 | 0.3 ± 2.2 | 0.3 ± 2.2 | 0.5 ± 2.2 | -0.1 ± 1.9 |
| Week 4: Change from baseline (Chloride) | -0.3 ± 1.7 | -0.2 ± 1.8 | -0.7 ± 2.5 | 0.3 ± 2.2 | 0.2 ± 2.1 |
| Week 8: Change from baseline (Chloride) | 0.2 ± 1.9 | -0.3 ± 2.0 | -0.4 ± 1.8 | 0.5 ± 2.3 | 0.3 ± 1.6 |
| Week 12: Change from baseline (Chloride) | -0.5 ± 2.2 | -0.1 ± 2.2 | -0.3 ± 1.9 | 0.5 ± 2.3 | 0.8 ± 2.0 |
| Week 16: Change from baseline (Chloride) | -0.5 ± 1.8 | 0.2 ± 2.2 | 0.6 ± 2.6 | 0.1 ± 1.9 | 0.1 ± 2.2 |
Blood samples for clinical chemistry assessment were collected and sent to the central laboratory for analysis.
| umol/L | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline (Creatinine) | 68.8 ± 11.2 | 68.5 ± 11.7 | 68.1 ± 14.9 | 71.4 ± 11.3 | 70.1 ± 11.9 |
| Week 2: Change from baseline (Creatinine) | 0.8 ± 7.2 | -0.2 ± 8.9 | 2.9 ± 9.7 | 0.7 ± 6.5 | 0.6 ± 7.0 |
| Week 4: Change from baseline (Creatinine) | -0.9 ± 6.0 | 0.6 ± 8.1 | 2.7 ± 9.8 | 1.9 ± 7.8 | 0.2 ± 7.8 |
| Week 8: Change from baseline (Creatinine) | 1.0 ± 6.3 | -1.0 ± 7.8 | 4.8 ± 5.3 | 0.6 ± 7.8 | 0.5 ± 9.0 |
| Week 12: Change from baseline (Creatinine) | 0.7 ± 8.9 | 2.1 ± 7.7 | 4.2 ± 11.2 | -0.5 ± 7.4 | -2.8 ± 8.0 |
| Week 16: Change from baseline (Creatinine) | 0.1 ± 7.6 | 1.5 ± 6.9 | 6.5 ± 8.5 | -0.9 ± 8.2 | -0.2 ± 12.9 |
| Baseline (Bilirubin) | 9.1 ± 4.1 | 8.4 ± 2.9 | 8.9 ± 3.1 | 9.6 ± 5.0 | 8.1 ± 2.8 |
| Week 2: Change from baseline (Bilirubin) | -0.5 ± 2.2 | 0.1 ± 2.2 | 1.4 ± 2.0 | 1.1 ± 3.3 | 1.7 ± 2.5 |
| Week 4: Change from baseline (Bilirubin) | -0.2 ± 2.6 | 0.4 ± 2.7 | 2.3 ± 2.8 | 1.0 ± 3.3 | 1.3 ± 3.0 |
| Week 8: Change from baseline (Bilirubin) | -0.1 ± 2.8 | 0.1 ± 2.1 | 1.8 ± 2.1 | 0.3 ± 3.1 | 0.9 ± 2.6 |
| Week 12: Change from baseline (Bilirubin) | -0.1 ± 2.4 | 0.7 ± 2.4 | 0.8 ± 2.7 | -0.2 ± 3.8 | 1.0 ± 2.7 |
| Week 16: Change from baseline (Bilirubin) | 0.2 ± 2.4 | -0.3 ± 3.4 | 0.8 ± 2.8 | -0.8 ± 3.7 | -0.4 ± 2.5 |
Blood samples for clinical chemistry assessment were collected and sent to the central laboratory for analysis.
| U/L | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline (Creatine Kinase) | 102.5 ± 117.2 | 91.6 ± 55.6 | 104.2 ± 62.0 | 161.8 ± 291.4 | 139.8 ± 159.3 |
| Week 2: Change from baseline (Creatine Kinase) | 28.2 ± 161.8 | 7.1 ± 45.5 | 8.7 ± 59.6 | -39.2 ± 280.5 | -44.3 ± 154.1 |
| Week 4: Change from baseline (Creatine Kinase) | -1.3 ± 36.8 | 2.7 ± 23.4 | 4.3 ± 44.2 | -30.2 ± 293.1 | -40.1 ± 163.0 |
| Week 8: Change from baseline (Creatine Kinase) | 15.5 ± 106.6 | 30.6 ± 127.3 | 158.1 ± 580.1 | -36.9 ± 275.8 | 4.0 ± 76.1 |
| Week 12: Change from baseline (Creatine Kinase) | 7.2 ± 49.7 | 16.1 ± 44.7 | 11.7 ± 116.5 | -13.3 ± 77.4 | -40.3 ± 174.5 |
| Week 16: Change from baseline (Creatine Kinase) | 7.3 ± 37.3 | 3.2 ± 34.3 | 5.6 ± 54.8 | -48.8 ± 267.0 | -44.1 ± 172.2 |
| Baseline (Alkaline Phosphatase) | 79.8 ± 24.1 | 85.9 ± 18.4 | 80.6 ± 19.4 | 91.3 ± 43.4 | 86.1 ± 25.5 |
| Week 2: Change from baseline (Alkaline Phosphatase) | -1.5 ± 8.4 | -1.9 ± 14.6 | -2.2 ± 6.3 | -2.5 ± 6.7 | -3.0 ± 8.2 |
| Week 4: Change from baseline (Alkaline Phosphatase) | -1.1 ± 6.1 | -5.2 ± 8.6 | 3.2 ± 13.1 | -3.8 ± 8.1 | -4.1 ± 8.8 |
| Week 8: Change from baseline (Alkaline Phosphatase) | -2.0 ± 8.5 | -5.0 ± 10.8 | -1.0 ± 6.2 | -5.1 ± 10.8 | -4.5 ± 12.0 |
| Week 12: Change from baseline (Alkaline Phosphatase) | -0.5 ± 8.2 | -3.2 ± 8.9 | 0.2 ± 11.5 | -4.4 ± 11.8 | -4.5 ± 8.1 |
| Week 16: Change from baseline (Alkaline Phosphatase) | -0.1 ± 8.5 | -0.6 ± 14.2 | -4.9 ± 10.4 | -0.1 ± 9.6 | -2.6 ± 8.0 |
| Baseline (Aspartate Aminotransferase) | 24.7 ± 6.0 | 24.4 ± 6.5 | 24.4 ± 5.1 | 24.8 ± 8.0 | 24.9 ± 6.0 |
| Week 2: Change from baseline (Aspartate Aminotransferase) | 0.9 ± 7.1 | 0.0 ± 4.0 | 0.1 ± 4.2 | -2.0 ± 7.6 | -2.3 ± 6.1 |
| Week 4: Change from baseline (Aspartate Aminotransferase) | 1.5 ± 6.3 | -0.2 ± 3.8 | 4.6 ± 17.7 | -1.8 ± 6.7 | -0.3 ± 6.9 |
| Week 8: Change from baseline (Aspartate Aminotransferase) | -1.3 ± 5.0 | -0.5 ± 4.7 | 3.4 ± 24.2 | -1.8 ± 6.9 | -1.2 ± 5.2 |
| Week 12: Change from baseline (Aspartate Aminotransferase) | -1.1 ± 4.3 | 0.3 ± 3.5 | 0.9 ± 8.1 | -1.8 ± 4.7 | -2.0 ± 7.6 |
| Week 16: Change from baseline (Aspartate Aminotransferase) | 0.7 ± 5.1 | 0.9 ± 7.5 | -2.4 ± 3.6 | -0.2 ± 8.5 | -2.2 ± 5.3 |
| Baseline (Alanine Aminotransferase) | 27.0 ± 8.7 | 24.0 ± 7.6 | 23.9 ± 10.0 | 24.4 ± 10.0 | 25.9 ± 9.0 |
| Week 2: Change from baseline (Alanine Aminotransferase) | 0.8 ± 10.6 | -0.1 ± 5.1 | -0.7 ± 5.6 | -2.1 ± 6.7 | -3.0 ± 7.6 |
| Week 4: Change from baseline (Alanine Aminotransferase) | 3.5 ± 11.6 | -1.0 ± 5.5 | 16.4 ± 70.2 | -2.1 ± 5.3 | -1.1 ± 9.5 |
| Week 8: Change from baseline (Alanine Aminotransferase) | -0.7 ± 6.1 | -0.3 ± 5.2 | 0.6 ± 12.2 | -0.4 ± 9.2 | -0.7 ± 10.6 |
| Week 12: Change from baseline (Alanine Aminotransferase) | -0.5 ± 7.4 | 0.7 ± 6.0 | 4.3 ± 21.0 | -0.6 ± 6.8 | -1.2 ± 9.1 |
| Week 16: Change from baseline (Alanine Aminotransferase) | 2.5 ± 13.1 | 2.0 ± 9.1 | -3.5 ± 6.9 | 3.1 ± 12.0 | -2.4 ± 6.7 |
| Baseline (Gamma Glutamyl Transferase ) | 24.6 ± 17.4 | 25.1 ± 15.0 | 19.3 ± 15.3 | 25.5 ± 23.2 | 25.9 ± 28.0 |
| Week 2: Change from baseline (Gamma Glutamyl Transferase) | -0.2 ± 11.3 | 0.0 ± 7.1 | -1.9 ± 6.7 | -2.7 ± 8.4 | -1.0 ± 7.6 |
| Week 4: Change from baseline (Gamma Glutamyl Transferase) | 3.0 ± 14.8 | -0.6 ± 9.1 | 3.6 ± 14.7 | -3.5 ± 10.6 | 1.4 ± 14.6 |
| Week 8: Change from baseline (Gamma Glutamyl Transferase) | -1.5 ± 6.4 | 0.1 ± 9.2 | 0.6 ± 5.9 | -2.8 ± 13.6 | 3.3 ± 22.6 |
| Week 12: Change from baseline (Gamma Glutamyl Transferase) | -1.2 ± 10.7 | 1.5 ± 9.8 | 4.8 ± 13.2 | -3.0 ± 14.3 | 1.3 ± 16.2 |
| Week 16: Change from baseline (Gamma Glutamyl Transferase) | -0.7 ± 8.8 | 2.2 ± 10.1 | 1.8 ± 14.4 | -0.7 ± 10.1 | -0.2 ± 16.4 |
Blood samples for clinical chemistry assessment were collected and sent to the central laboratory for analysis.
| g/L | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline (Protein) | 67.4 ± 4.0 | 67.5 ± 4.3 | 66.5 ± 5.1 | 67.7 ± 4.3 | 67.0 ± 4.7 |
| Week 2: Change from baseline (Protein) | -1.7 ± 2.9 | -2.1 ± 4.6 | -0.4 ± 3.7 | -1.5 ± 2.9 | -2.1 ± 3.7 |
| Week 4: Change from baseline (Protein) | -1.8 ± 3.0 | -1.5 ± 4.1 | 0.2 ± 3.3 | -1.6 ± 2.7 | -1.5 ± 3.5 |
| Week 8: Change from baseline (Protein) | -1.5 ± 3.4 | -2.3 ± 4.2 | -1.7 ± 4.2 | -2.0 ± 3.8 | -2.4 ± 3.3 |
| Week 12: Change from baseline (Protein) | -1.5 ± 3.0 | -1.5 ± 3.9 | -0.7 ± 4.6 | -1.7 ± 3.4 | -1.8 ± 3.2 |
| Week 16: Change from baseline (Protein) | -1.0 ± 3.2 | -1.6 ± 4.1 | -1.9 ± 5.0 | -1.8 ± 3.7 | -1.7 ± 4.0 |
| Baseline (Albumin) | 44.7 ± 2.1 | 44.9 ± 2.8 | 43.6 ± 2.4 | 45.2 ± 2.4 | 44.2 ± 3.0 |
| Week 2: Change from baseline (Albumin) | -1.3 ± 1.9 | -1.4 ± 2.6 | -0.1 ± 2.4 | -0.9 ± 1.8 | -1.3 ± 2.4 |
| Week 4: Change from baseline (Albumin) | -0.9 ± 2.1 | -1.0 ± 2.3 | 0.5 ± 2.2 | -0.8 ± 1.9 | -0.7 ± 2.6 |
| Week 8: Change from baseline (Albumin) | -0.8 ± 2.2 | -1.2 ± 2.7 | -0.9 ± 2.5 | -0.8 ± 2.6 | -1.3 ± 2.2 |
| Week 12: Change from baseline (Albumin) | -0.6 ± 1.9 | -0.7 ± 2.1 | 0.3 ± 2.6 | -0.6 ± 2.5 | -0.7 ± 2.2 |
| Week 16: Change from baseline (Albumin) | 0.0 ± 2.0 | -0.4 ± 2.0 | 0.1 ± 3.1 | -0.6 ± 2.3 | -0.4 ± 2.8 |
Blood samples for clinical chemistry assessment were collected and sent to the central laboratory for analysis.
| mmol/mol | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline | 39.22 ± 8.09 | 39.05 ± 5.82 | 35.84 ± 3.39 | 38.78 ± 5.65 | 40.88 ± 10.97 |
| Week 2: Change from baseline | -0.42 ± 1.46 | 0.04 ± 1.18 | 0.19 ± 1.46 | -0.08 ± 1.35 | -0.21 ± 2.32 |
| Week 4: Change from baseline | -0.29 ± 1.91 | 0.00 ± 1.96 | 0.06 ± 1.47 | -0.02 ± 1.55 | -0.43 ± 4.24 |
| Week 8: Change from baseline | -0.40 ± 2.38 | 0.26 ± 2.16 | 0.62 ± 2.13 | -0.13 ± 1.72 | -0.28 ± 5.11 |
| Week 12: Change from baseline | 0.07 ± 1.96 | 0.84 ± 3.01 | 1.57 ± 2.46 | 0.55 ± 2.30 | -0.94 ± 5.33 |
| Week 16: Change from baseline | -0.64 ± 2.41 | 0.69 ± 2.64 | 1.16 ± 2.13 | -0.04 ± 2.22 | -1.07 ± 5.65 |
Blood for assessment of bone turnover markers was collected and sent to the central laboratory for analysis.
| ug/L | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline (Bone Specific Alkaline Phosphatase) | 12.17 ± 5.08 | 13.01 ± 5.09 | 13.94 ± 4.67 | 13.37 ± 4.69 | 13.36 ± 4.83 |
| Week 12: Change from baseline (Bone Specific Alkaline Phosphatase) | 0.48 ± 2.22 | 0.34 ± 4.24 | -0.68 ± 3.36 | -0.43 ± 2.50 | -0.11 ± 2.73 |
| Week 16: Change from baseline (Bone Specific Alkaline Phosphatase) | 0.86 ± 3.57 | 1.22 ± 7.58 | -1.18 ± 2.49 | 0.84 ± 3.55 | 0.48 ± 2.98 |
| Baseline (Procollagen 1 N-Terminal Propeptide) | 58.1 ± 23.3 | 68.0 ± 24.7 | 67.6 ± 15.6 | 68.6 ± 29.3 | 59.5 ± 23.6 |
| Week 12: Change from baseline (Procollagen 1 N-Terminal Propeptide) | 5.0 ± 14.5 | 0.5 ± 10.9 | -5.7 ± 15.9 | -2.1 ± 13.7 | -0.7 ± 10.9 |
| Week 16: Change from baseline (Procollagen 1 N-Terminal Propeptide) | 3.6 ± 20.2 | -1.9 ± 9.7 | -0.9 ± 19.6 | -2.5 ± 15.4 | 0.0 ± 11.7 |
Urine for urinalysis was collected and sent to the central laboratory for analysis. Urine pH was measured on a pH scale.
| pH | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline (pH) | 6.00 ± 0.83 | 6.10 ± 0.89 | 6.09 ± 0.92 | 6.21 ± 0.75 | 6.08 ± 0.72 |
| Week 2: Change from baseline (pH) | 0.10 ± 0.70 | 0.26 ± 0.90 | -0.15 ± 0.95 | -0.30 ± 0.83 | -0.20 ± 0.83 |
| Week 4: Change from baseline (pH) | -0.11 ± 0.85 | 0.18 ± 1.31 | -0.09 ± 0.80 | -0.25 ± 0.83 | -0.09 ± 0.89 |
| Week 12: Change from baseline (pH) | -0.05 ± 0.89 | 0.18 ± 1.06 | -0.19 ± 0.83 | -0.21 ± 0.78 | -0.06 ± 0.79 |
| Week 16: Change from baseline (pH) | 0.05 ± 1.13 | 0.00 ± 1.12 | -0.03 ± 0.90 | -0.19 ± 0.84 | 0.07 ± 1.04 |
Urine for urinalysis was collected and sent to the central laboratory for analysis.
| Unitless | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline (Specific Gravity) | 1.0167 ± 0.0063 | 1.0167 ± 0.0083 | 1.0166 ± 0.0063 | 1.0154 ± 0.0064 | 1.0171 ± 0.0084 |
| Week 2: Change from baseline (Specific Gravity) | -0.0002 ± 0.0066 | -0.0011 ± 0.0085 | 0.0001 ± 0.0060 | 0.0005 ± 0.0068 | -0.0006 ± 0.0060 |
| Week 4: Change from baseline (Specific Gravity) | -0.0008 ± 0.0078 | 0.0012 ± 0.0086 | -0.0026 ± 0.0063 | 0.0015 ± 0.0067 | 0.0003 ± 0.0079 |
| Week 12: Change from baseline (Specific Gravity) | 0.0020 ± 0.0068 | 0.0015 ± 0.0102 | -0.0012 ± 0.0060 | 0.0002 ± 0.0068 | 0.0011 ± 0.0072 |
| Week 16: Change from baseline (Specific Gravity) | 0.0009 ± 0.0088 | 0.0002 ± 0.0093 | -0.0011 ± 0.0059 | 0.0020 ± 0.0066 | -0.0006 ± 0.0066 |
Urine for urinalysis was collected and sent to the central laboratory for analysis. Clinical relevance was judged by the investigator. Assessment was done using standard laboratory practice. For evaluation of the chemical properties of the urine sample test strips were used which have test pads of chemicals that change color when they come in contact with reagents. The degree of color change correlates with the amount of reagent present. Each color block represents a range of values. Range and direction of scores for reagents nitrite and urobilinogen: negative = normal; positive = abnormal. Range and direction of scores for all other reagents tested: negative = normal; trace, 1+, 2+, 3+ = abnormal, the higher the value, the higher the concentration of the reagent tested.
| Participants | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline (Glucose): Negative | 46 | 30 | 17 | 49 | 48 |
| Baseline (Glucose): Trace | 1 | 0 | 0 | 0 | 1 |
| Baseline (Glucose): 1+ | 0 | 1 | 0 | 0 | 0 |
| Baseline (Glucose): 2+ | 0 | 0 | 0 | 0 | 0 |
| Baseline (Glucose): 3+ | 0 | 0 | 0 | 0 | 2 |
| Week 2 (Glucose): Negative | 44 | 31 | 17 | 52 | 49 |
| Week 2 (Glucose): Trace | 0 | 0 | 0 | 0 | 0 |
| Week 2 (Glucose): 1+ | 0 | 0 | 0 | 0 | 1 |
| Week 2 (Glucose): 2+ | 0 | 0 | 0 | 0 | 0 |
| Week 2 (Glucose): 3+ | 0 | 0 | 0 | 0 | 1 |
| Week 4 (Glucose): Negative | 45 | 30 | 17 | 51 | 46 |
| Week 4 (Glucose): Trace | 0 | 1 | 0 | 0 | 0 |
| Week 4 (Glucose): 1+ | 0 | 0 | 0 | 0 | 0 |
| Week 4 (Glucose): 2+ | 0 | 0 | 0 | 0 | 0 |
| Week 4 (Glucose): 3+ | 0 | 0 | 0 | 0 | 2 |
| Week 12 (Glucose): Negative | 43 | 30 | 16 | 47 | 40 |
| Week 12 (Glucose): Trace | 0 | 0 | 0 | 1 | 1 |
| Week 12 (Glucose): 1+ | 0 | 0 | 0 | 0 | 1 |
| Week 12 (Glucose): 2+ | 0 | 0 | 0 | 0 | 0 |
| Week 12 (Glucose): 3+ | 0 | 0 | 0 | 1 | 2 |
| Week 16 (Glucose): Negative | 40 | 29 | 16 | 50 | 43 |
| Week 16 (Glucose): Trace | 0 | 1 | 0 | 0 | 0 |
| Week 16 (Glucose): 1+ | 1 | 0 | 0 | 0 | 0 |
| Week 16 (Glucose): 2+ | 0 | 0 | 0 | 0 | 0 |
| Week 16 (Glucose): 3+ | 0 | 0 | 0 | 1 | 1 |
| Baseline (Bilirubin): Negative | 47 | 31 | 17 | 49 | 51 |
| Baseline (Bilirubin): 1+ | 0 | 0 | 0 | 0 | 0 |
| Week 2 (Bilirubin): Negative | 44 | 31 | 17 | 52 | 51 |
| Week 2 (Bilirubin): 1+ | 0 | 0 | 0 | 0 | 0 |
| Week 4 (Bilirubin): Negative | 45 | 31 | 17 | 51 | 48 |
| Week 4 (Bilirubin): 1+ | 0 | 0 | 0 | 0 | 0 |
| Week 12 (Bilirubin): Negative | 43 | 30 | 16 | 49 | 44 |
| Week 12 (Bilirubin): 1+ | 0 | 0 | 0 | 0 | 0 |
| Week 16 (Bilirubin): Negative | 41 | 29 | 16 | 51 | 44 |
| Week 16 (Bilirubin): 1+ | 0 | 1 | 0 | 0 | 0 |
| Baseline (Ketones): Negative | 46 | 31 | 17 | 48 | 50 |
| Baseline (Ketones): Trace | 1 | 0 | 0 | 1 | 1 |
| Week 2 (Ketones): Negative | 44 | 31 | 17 | 51 | 50 |
| Week 2 (Ketones): Trace | 0 | 0 | 0 | 1 | 1 |
| Week 4 (Ketones): Negative | 45 | 31 | 17 | 50 | 48 |
| Week 4 (Ketones): Trace | 0 | 0 | 0 | 1 | 0 |
| Week 12 (Ketones): Negative | 42 | 30 | 16 | 48 | 43 |
| Week 12 (Ketones): Trace | 1 | 0 | 0 | 1 | 1 |
| Week 16 (Ketones): Negative | 41 | 30 | 16 | 50 | 44 |
| Week 16 (Ketones): Trace | 0 | 0 | 0 | 1 | 0 |
| Baseline (Occult Blood): Negative | 46 | 28 | 15 | 42 | 47 |
| Baseline (Occult Blood): Trace | 0 | 3 | 1 | 3 | 4 |
| Baseline (Occult Blood): 1+ | 1 | 0 | 0 | 3 | 0 |
| Baseline (Occult Blood): 2+ | 0 | 0 | 0 | 1 | 0 |
| Baseline (Occult Blood): 3+ | 0 | 0 | 1 | 0 | 0 |
| Week 2 (Occult Blood): Negative | 42 | 29 | 17 | 45 | 47 |
| Week 2 (Occult Blood): Trace | 1 | 2 | 0 | 1 | 3 |
| Week 2 (Occult Blood): 1+ | 1 | 0 | 0 | 5 | 1 |
| Week 2 (Occult Blood): 2+ | 0 | 0 | 0 | 1 | 0 |
| Week 2 (Occult Blood): 3+ | 0 | 0 | 0 | 0 | 0 |
| Week 4 (Occult Blood): Negative | 43 | 28 | 17 | 42 | 47 |
| Week 4 (Occult Blood): Trace | 2 | 1 | 0 | 5 | 1 |
| Week 4 (Occult Blood): 1+ | 0 | 2 | 0 | 3 | 0 |
| Week 4 (Occult Blood): 2+ | 0 | 0 | 0 | 0 | 0 |
| Week 4 (Occult Blood): 3+ | 0 | 0 | 0 | 1 | 0 |
| Week 12 (Occult Blood): Negative | 40 | 30 | 13 | 40 | 42 |
| Week 12 (Occult Blood): Trace | 1 | 0 | 1 | 5 | 2 |
| Week 12 (Occult Blood): 1+ | 2 | 0 | 1 | 3 | 0 |
| Week 12 (Occult Blood): 2+ | 0 | 0 | 1 | 1 | 0 |
| Week 12 (Occult Blood): 3+ | 0 | 0 | 0 | 0 | 0 |
| Week 16 (Occult Blood): Negative | 38 | 27 | 14 | 45 | 39 |
| Week 16 (Occult Blood): Trace | 2 | 3 | 1 | 3 | 4 |
| Week 16 (Occult Blood): 1+ | 0 | 0 | 0 | 3 | 1 |
| Week 16 (Occult Blood): 2+ | 1 | 0 | 0 | 0 | 0 |
| Week 16 (Occult Blood): 3+ | 0 | 0 | 1 | 0 | 0 |
| Baseline (Protein): Negative | 45 | 31 | 16 | 48 | 49 |
| Baseline (Protein): Trace | 2 | 0 | 1 | 1 | 1 |
| Baseline (Protein): 1+ | 0 | 0 | 0 | 0 | 1 |
| Baseline (Protein): 2+ | 0 | 0 | 0 | 0 | 0 |
| Baseline (Protein): 3+ | 0 | 0 | 0 | 0 | 0 |
| Week 2 (Protein): Negative | 44 | 31 | 17 | 52 | 49 |
| Week 2 (Protein): Trace | 0 | 0 | 0 | 0 | 0 |
| Week 2 (Protein): 1+ | 0 | 0 | 0 | 0 | 0 |
| Week 2 (Protein): 2+ | 0 | 0 | 0 | 0 | 2 |
| Week 2 (Protein): 3+ | 0 | 0 | 0 | 0 | 0 |
| Week 4 (Protein): Negative | 44 | 31 | 17 | 49 | 45 |
| Week 4 (Protein): Trace | 0 | 0 | 0 | 2 | 3 |
| Week 4 (Protein): 1+ | 1 | 0 | 0 | 0 | 0 |
| Week 4 (Protein): 2+ | 0 | 0 | 0 | 0 | 0 |
| Week 4 (Protein): 3+ | 0 | 0 | 0 | 0 | 0 |
| Week 12 (Protein): Negative | 41 | 30 | 14 | 47 | 43 |
| Week 12 (Protein): Trace | 1 | 0 | 0 | 1 | 1 |
| Week 12 (Protein): 1+ | 1 | 0 | 2 | 1 | 0 |
| Week 12 (Protein): 2+ | 0 | 0 | 0 | 0 | 0 |
| Week 12 (Protein): 3+ | 0 | 0 | 0 | 0 | 0 |
| Week 16 (Protein): Negative | 39 | 30 | 15 | 50 | 43 |
| Week 16 (Protein): Trace | 1 | 0 | 0 | 0 | 1 |
| Week 16 (Protein): 1+ | 0 | 0 | 0 | 1 | 0 |
| Week 16 (Protein): 2+ | 0 | 0 | 1 | 0 | 0 |
| Week 16 (Protein): 3+ | 1 | 0 | 0 | 0 | 0 |
| Baseline (Urobilinogen): Negative | 47 | 31 | 17 | 49 | 51 |
| Week 2 (Urobilinogen): Negative | 44 | 31 | 17 | 52 | 51 |
| Week 4 (Urobilinogen): Negative | 45 | 31 | 17 | 51 | 48 |
| Week 12 (Urobilinogen): Negative | 43 | 30 | 16 | 49 | 44 |
| Week 16 (Urobilinogen): Negative | 41 | 30 | 16 | 51 | 44 |
| Baseline (Nitrite): Negative | 47 | 29 | 17 | 48 | 48 |
| Baseline (Nitrite): Positive | 0 | 2 | 0 | 1 | 3 |
| Week 2 (Nitrite): Negative | 44 | 29 | 17 | 51 | 47 |
| Week 2 (Nitrite): Positive | 0 | 2 | 0 | 1 | 4 |
| Week 4 (Nitrite): Negative | 45 | 29 | 17 | 50 | 47 |
| Week 4 (Nitrite): Positive | 0 | 2 | 0 | 1 | 1 |
| Week 12 (Nitrite): Negative | 42 | 29 | 16 | 49 | 42 |
| Week 12 (Nitrite): Positive | 1 | 1 | 0 | 0 | 2 |
| Week 16 (Nitrite): Negative | 41 | 30 | 16 | 51 | 42 |
| Week 16 (Nitrite): Positive | 0 | 0 | 0 | 0 | 2 |
Urine for urinalysis was collected and sent to the central laboratory for analysis. Results are reported according to the amount present in the microscope's field of view at high magnification (/HPF \[high-power field\]).
| cells/HPF | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline (Erythrocytes (/HPF)) | 1.3 ± 1.5 | 0.8 ± 1.1 | 2.0 ± 2.6 | 1.5 ± 2.4 | 0.6 ± 0.7 |
| Week 2: Change from baseline (Erythrocytes (/HPF)) | -0.6 ± 2.6 | -0.6 ± 0.5 | -1.0 ± 1.4 | -0.8 ± 4.0 | 0.9 ± 3.0 |
| Week 4: Change from baseline (Erythrocytes (/HPF)) | -0.1 ± 1.6 | 0.5 ± 1.3 | -2.7 ± 3.1 | -0.5 ± 3.1 | 0.3 ± 1.1 |
| Week 12: Change from baseline (Erythrocytes (/HPF)) | -0.4 ± 2.2 | -0.4 ± 0.8 | 0.4 ± 0.5 | 1.4 ± 3.7 | 0.2 ± 1.5 |
| Week 16: Change from baseline (Erythrocytes (/HPF)) | -0.3 ± 2.1 | -0.7 ± 1.2 | -1.5 ± 2.4 | 0.3 ± 2.1 | 0.1 ± 0.3 |
| Baseline (Leukocytes (/HPF)) | 9.5 ± 16.2 | 2.6 ± 4.3 | 1.6 ± 1.7 | 5.3 ± 11.9 | 3.0 ± 5.8 |
| Week 2: Change from baseline (Leukocytes (/HPF)) | -6.7 ± 15.9 | 0.0 ± 3.6 | 0.5 ± 2.1 | -1.0 ± 2.7 | -0.4 ± 6.4 |
| Week 4: Change from baseline (Leukocytes (/HPF)) | -6.0 ± 20.9 | 1.0 ± 1.0 | 6.3 ± 11.8 | 0.3 ± 4.1 | 0.8 ± 5.8 |
| Week 12: Change from baseline (Leukocytes (/HPF)) | 6.4 ± 47.9 | 3.5 ± 6.7 | 0.6 ± 3.0 | 0.6 ± 2.3 | -1.5 ± 5.1 |
| Week 16: Change from baseline (Leukocytes (/HPF)) | -7.6 ± 21.9 | 3.0 ± 4.4 | 3.0 ± 4.2 | 0.6 ± 1.3 | 13.3 ± 33.4 |
Urine for urinalysis was collected and sent to the central laboratory for analysis. Results are reported according to the amount present in the microscope's field of view at low magnification (/LPF \[low-power field\]).
| cells/LPF | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline (Hyaline Casts (/LPF) | 1.9 ± 2.0 | 0.8 ± 1.6 | 0.1 ± 0.4 | 0.8 ± 1.4 | 1.7 ± 6.2 |
| Week 2: Change from baseline (Hyaline Casts (/LPF)) | -1.1 ± 2.7 | -0.6 ± 1.5 | 0.0 ± 0.0 | -0.1 ± 0.6 | 0.1 ± 1.5 |
| Week 4: Change from baseline (Hyaline Casts (/LPF)) | -0.2 ± 3.6 | -0.5 ± 1.0 | 5.3 ± 6.8 | 0.3 ± 1.8 | -0.4 ± 1.7 |
| Week 12: Change from baseline (Hyaline Casts (/LPF)) | -0.3 ± 2.8 | -0.1 ± 1.5 | 2.2 ± 4.4 | -0.3 ± 0.8 | -2.8 ± 9.0 |
| Week 16: Change from baseline (Hyaline Casts (/LPF)) | -1.2 ± 2.9 | 0.7 ± 1.2 | 0.5 ± 1.0 | 0.1 ± 0.8 | -0.2 ± 0.8 |
Urine for urinalysis was collected and sent to the central laboratory for analysis. The evaluation of components in the urine samples such as bacteria, yeast, red blood cells (RBC), white blood cells (WBC), casts and crystals was performed by microscopy. Results are reported according to the amount present in the microscope's field of view at low magnification (/LPF \[low-power field\]) and high magnification (/HPF \[high-power field\]). Range and direction of scores microscopic identification of urine components: * Bacteria: none seen, 1+, 2+, 3+,4+, TNTC (too numerous to count). * Other urine components: none seen=normal; few, moderate, many, TNTC = abnormal. The higher the value, the higher the concentration of the component evaluated.
| Participants | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| Baseline (Bacteria(/HPF)): None seen | 4 | 4 | 2 | 9 | 7 |
| Baseline (Bacteria(/HPF)): 1+ | 4 | 3 | 1 | 6 | 5 |
| Baseline (Bacteria(/HPF)): 2+ | 0 | 1 | 1 | 1 | 2 |
| Baseline (Bacteria(/HPF)): 3+ | 0 | 1 | 0 | 0 | 2 |
| Baseline (Bacteria(/HPF)): 4+ | 0 | 0 | 1 | 1 | 1 |
| Baseline (Bacteria(/HPF)): TNTC | 1 | 2 | 0 | 0 | 2 |
| Week 2 (Bacteria(/HPF)): None seen | 3 | 3 | 1 | 5 | 6 |
| Week 2 (Bacteria(/HPF)): 1+ | 1 | 2 | 1 | 4 | 4 |
| Week 2 (Bacteria(/HPF)): 2+ | 1 | 2 | 1 | 0 | 6 |
| Week 2 (Bacteria(/HPF)): 3+ | 0 | 1 | 0 | 1 | 1 |
| Week 2 (Bacteria(/HPF)): 4+ | 2 | 0 | 0 | 0 | 0 |
| Week 2 (Bacteria(/HPF)): TNTC | 1 | 1 | 0 | 1 | 1 |
| Week 4 (Bacteria(/HPF)): None seen | 7 | 3 | 1 | 9 | 2 |
| Week 4 (Bacteria(/HPF)): 1+ | 0 | 0 | 1 | 1 | 3 |
| Week 4 (Bacteria(/HPF)): 2+ | 2 | 0 | 1 | 4 | 3 |
| Week 4 (Bacteria(/HPF)): 3+ | 0 | 0 | 0 | 0 | 1 |
| Week 4 (Bacteria(/HPF)): 4+ | 0 | 0 | 0 | 0 | 2 |
| Week 4 (Bacteria(/HPF)): TNTC | 2 | 3 | 0 | 1 | 2 |
| Week 12 (Bacteria(/HPF)): None seen | 1 | 3 | 3 | 11 | 3 |
| Week 12 (Bacteria(/HPF)): 1+ | 7 | 2 | 3 | 3 | 3 |
| Week 12 (Bacteria(/HPF)): 2+ | 1 | 0 | 2 | 3 | 5 |
| Week 12 (Bacteria(/HPF)): 3+ | 1 | 0 | 0 | 1 | 0 |
| Week 12 (Bacteria(/HPF)): 4+ | 0 | 1 | 0 | 0 | 0 |
| Week 12 (Bacteria(/HPF)): TNTC | 2 | 2 | 0 | 0 | 1 |
| Week 16 (Bacteria(/HPF)): None seen | 2 | 3 | 2 | 6 | 4 |
| Week 16 (Bacteria(/HPF)): 1+ | 5 | 0 | 0 | 3 | 3 |
| Week 16 (Bacteria(/HPF)): 2+ | 4 | 2 | 1 | 1 | 1 |
| Week 16 (Bacteria(/HPF)): 3+ | 1 | 0 | 0 | 1 | 2 |
| Week 16 (Bacteria(/HPF)): 4+ | 1 | 1 | 2 | 0 | 3 |
| Week 16 (Bacteria(/HPF)): TNTC | 0 | 0 | 0 | 1 | 1 |
| Baseline (Yeast Cells(/HPF)): None seen | 9 | 11 | 5 | 17 | 19 |
| Baseline (Yeast Cells(/HPF)): Few | 0 | 0 | 0 | 0 | 0 |
| Week 2 (Yeast Cells(/HPF)): None seen | 8 | 9 | 3 | 11 | 17 |
| Week 2 (Yeast Cells(/HPF)): Few | 0 | 0 | 0 | 0 | 1 |
| Week 4 (Yeast Cells(/HPF)): None seen | 11 | 6 | 3 | 15 | 13 |
| Week 4 (Yeast Cells(/HPF)): Few | 0 | 0 | 0 | 0 | 0 |
| Week 12 (Yeast Cells(/HPF)): None seen | 12 | 8 | 8 | 18 | 12 |
| Week 12 (Yeast Cells(/HPF)): Few | 0 | 0 | 0 | 0 | 0 |
| Week 16 (Yeast Cells(/HPF)): None seen | 13 | 6 | 5 | 12 | 14 |
| Week 16 (Yeast Cells(/HPF)): Few | 0 | 0 | 0 | 0 | 0 |
| Baseline (Granular Casts(/LPF)): None seen | 9 | 11 | 5 | 17 | 19 |
| Week 2: (Granular Casts(/LPF)): None seen | 8 | 9 | 3 | 11 | 18 |
| Week 4: (Granular Casts(/LPF)): None seen | 11 | 6 | 3 | 15 | 13 |
| Week 12: (Granular Casts(/LPF)): None seen | 12 | 8 | 8 | 18 | 12 |
| Week 16: (Granular Casts(/LPF)): None seen | 13 | 6 | 5 | 12 | 14 |
| Baseline (RBC Casts(/LPF)): None seen | 9 | 11 | 5 | 17 | 19 |
| Week 2 (RBC Casts(/LPF)): None seen | 8 | 9 | 3 | 11 | 18 |
| Week 4 (RBC Casts(/LPF)): None seen | 11 | 6 | 3 | 15 | 13 |
| Week 12 (RBC Casts(/LPF)): None seen | 12 | 8 | 8 | 18 | 12 |
| Week 16 (RBC Casts(/LPF)): None seen | 13 | 6 | 5 | 12 | 14 |
| Baseline (Waxy Casts(/LPF)): None seen | 9 | 11 | 5 | 17 | 19 |
| Week 2 (Waxy Casts(/LPF)): None seen | 8 | 9 | 3 | 11 | 18 |
| Week 4 (Waxy Casts(/LPF)): None seen | 11 | 6 | 3 | 15 | 13 |
| Week 12 (Waxy Casts(/LPF)): None seen | 12 | 8 | 8 | 18 | 12 |
| Week 16 (Waxy Casts(/LPF)): None seen | 13 | 6 | 5 | 12 | 14 |
| Baseline (WBC Casts(/LPF)): None seen | 9 | 11 | 5 | 17 | 19 |
| Week 2 (WBC Casts(/LPF)): None seen | 8 | 9 | 3 | 11 | 18 |
| Week 4 (WBC Casts(/LPF)): None seen | 11 | 6 | 3 | 15 | 13 |
| Week 12 (WBC Casts(/LPF)): None seen | 12 | 8 | 8 | 18 | 12 |
| Week 16 (WBC Casts(/LPF)): None seen | 13 | 6 | 5 | 12 | 14 |
| Baseline (Calcium Oxalate Crystals(/HPF)): None seen | 8 | 11 | 5 | 13 | 16 |
| Baseline (Calcium Oxalate Crystals(/HPF)): Few | 1 | 0 | 0 | 2 | 2 |
| Baseline (Calcium Oxalate Crystals(/HPF)): Moderate | 0 | 0 | 0 | 0 | 1 |
| Baseline (Calcium Oxalate Crystals(/HPF)): Many | 0 | 0 | 0 | 2 | 0 |
| Baseline (Calcium Oxalate Crystals(/HPF)): TNTC | 0 | 0 | 0 | 0 | 0 |
| Week 2 (Calcium Oxalate Crystals(/HPF)): None seen | 6 | 8 | 3 | 9 | 17 |
| Week 2 (Calcium Oxalate Crystals(/HPF)): Few | 2 | 0 | 0 | 1 | 0 |
| Week 2 (Calcium Oxalate Crystals(/HPF)): Moderate | 0 | 0 | 0 | 0 | 1 |
| Week 2 (Calcium Oxalate Crystals(/HPF)): Many | 0 | 1 | 0 | 1 | 0 |
| Week 2 (Calcium Oxalate Crystals(/HPF)): TNTC | 0 | 0 | 0 | 0 | 0 |
| Week 4 (Calcium Oxalate Crystals(/HPF)): None seen | 9 | 5 | 3 | 12 | 10 |
| Week 4 (Calcium Oxalate Crystals(/HPF)): Few | 0 | 0 | 0 | 1 | 1 |
| Week 4 (Calcium Oxalate Crystals(/HPF)): Moderate | 1 | 1 | 0 | 1 | 0 |
| Week 4 (Calcium Oxalate Crystals(/HPF)): Many | 1 | 0 | 0 | 1 | 1 |
| Week 4 (Calcium Oxalate Crystals(/HPF)): TNTC | 0 | 0 | 0 | 0 | 1 |
| Week 12 (Calcium Oxalate Crystals(/HPF)): None seen | 11 | 7 | 8 | 16 | 11 |
| Week 12 (Calcium Oxalate Crystals(/HPF)): Few | 1 | 0 | 0 | 0 | 1 |
| Week 12 (Calcium Oxalate Crystals(/HPF)): Moderate | 0 | 1 | 0 | 1 | 0 |
| Week 12 (Calcium Oxalate Crystals(/HPF)): Many | 0 | 0 | 0 | 1 | 0 |
| Week 12 (Calcium Oxalate Crystals(/HPF)): TNTC | 0 | 0 | 0 | 0 | 0 |
| Week 16 (Calcium Oxalate Crystals(/HPF)): None seen | 10 | 4 | 5 | 11 | 14 |
| Week 16 (Calcium Oxalate Crystals(/HPF)): Few | 2 | 2 | 0 | 0 | 0 |
| Week 16 (Calcium Oxalate Crystals(/HPF)): Moderate | 1 | 0 | 0 | 0 | 0 |
| Week 16 (Calcium Oxalate Crystals(/HPF)): Many | 0 | 0 | 0 | 1 | 0 |
| Week 16 (Calcium Oxalate Crystals(/HPF)): TNTC | 0 | 0 | 0 | 0 | 0 |
| Baseline (Triple Phosphate Crystals(/HPF)): None seen | 9 | 11 | 5 | 17 | 19 |
| Week 2 (Triple Phosphate Crystals(/HPF)): None seen | 8 | 9 | 3 | 11 | 18 |
| Week 4 (Triple Phosphate Crystals(/HPF)): None seen | 11 | 6 | 3 | 15 | 13 |
| Week 12 (Triple Phosphate Crystals(/HPF)): None seen | 12 | 8 | 8 | 18 | 12 |
| Week 16 (Triple Phosphate Crystals(/HPF)): None seen | 13 | 6 | 5 | 12 | 14 |
| Baseline (Uric Acid Crystals(/HPF)): None seen | 9 | 11 | 5 | 16 | 19 |
| Baseline (Uric Acid Crystals(/HPF)): Few | 0 | 0 | 0 | 1 | 0 |
| Baseline (Uric Acid Crystals(/HPF)): Moderate | 0 | 0 | 0 | 0 | 0 |
| Week 2 (Uric Acid Crystals(/HPF)): None seen | 8 | 9 | 3 | 11 | 18 |
| Week 2 (Uric Acid Crystals(/HPF)): Few | 0 | 0 | 0 | 0 | 0 |
| Week 2 (Uric Acid Crystals(/HPF)): Moderate | 0 | 0 | 0 | 0 | 0 |
| Week 4 (Uric Acid Crystals(/HPF)): None seen | 11 | 6 | 3 | 14 | 12 |
| Week 4 (Uric Acid Crystals(/HPF)): Few | 0 | 0 | 0 | 0 | 1 |
| Week 4 (Uric Acid Crystals(/HPF)): Moderate | 0 | 0 | 0 | 1 | 0 |
| Week 12 (Uric Acid Crystals(/HPF)): None seen | 11 | 8 | 8 | 18 | 12 |
| Week 12 (Uric Acid Crystals(/HPF)): Few | 1 | 0 | 0 | 0 | 0 |
| Week 12 (Uric Acid Crystals(/HPF)): Moderate | 0 | 0 | 0 | 0 | 0 |
| Week 16 (Uric Acid Crystals(/HPF)): None seen | 13 | 6 | 4 | 11 | 14 |
| Week 16 (Uric Acid Crystals(/HPF)): Few | 0 | 0 | 1 | 1 | 0 |
| Week 16 (Uric Acid Crystals(/HPF)): Moderate | 0 | 0 | 0 | 0 | 0 |
Collected over On or after first dosing with randomised study treatment up to Week 16. Adverse event reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to 1 year.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/47 (0%) | 2/47 (4.3%) | 18/47 (38.3%) |
| 40 mg Elinzanetant (BAY3427080) | 0/31 (0%) | 0/31 (0%) | 13/31 (41.9%) |
| 80 mg Elinzanetant (BAY3427080) | 0/17 (0%) | 1/17 (5.9%) | 14/17 (82.4%) |
| 120 mg Elinzanetant (BAY3427080) | 0/52 (0%) | 1/52 (1.9%) | 23/52 (44.2%) |
| 160 mg Elinzanetant (BAY3427080) | 0/52 (0%) | 1/52 (1.9%) | 23/52 (44.2%) |
| Event | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| NephrolithiasisRenal and urinary disorders | 0/47 | 0/31 | 1/17 | 0/52 | 0/52 |
| SepsisInfections and infestations | 1/47 | 0/31 | 0/17 | 0/52 | 0/52 |
| Infective exacerbation of chronic obstructive airways diseaseInfections and infestations | 1/47 | 0/31 | 0/17 | 0/52 | 0/52 |
| Tooth abscessInfections and infestations | 0/47 | 0/31 | 0/17 | 0/52 | 1/52 |
| MigraineNervous system disorders | 0/47 | 0/31 | 0/17 | 1/52 | 0/52 |
| Event | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) |
|---|---|---|---|---|---|
| HeadacheNervous system disorders | 6/47 | 3/31 | 2/17 | 6/52 | 4/52 |
| DiarrhoeaGastrointestinal disorders | 3/47 | 2/31 | 2/17 | 3/52 | 3/52 |
| NauseaGastrointestinal disorders | 2/47 | 2/31 | 2/17 | 1/52 | 2/52 |
| Herpes zosterInfections and infestations | 0/47 | 0/31 | 2/17 | 0/52 | 0/52 |
| SomnolenceNervous system disorders | 1/47 | 3/31 | 1/17 | 2/52 | 6/52 |
| FatigueGeneral disorders | 0/47 | 3/31 | 1/17 | 1/52 | 4/52 |
| NasopharyngitisInfections and infestations | 4/47 | 1/31 | 0/17 | 3/52 | 0/52 |
| Urinary tract infectionInfections and infestations | 1/47 | 2/31 | 0/17 | 2/52 | 2/52 |
| Arthropod biteInjury, poisoning and procedural complications | 1/47 | 2/31 | 0/17 | 1/52 | 1/52 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/47 | 2/31 | 0/17 | 0/52 | 2/52 |
| Age, Continuous(years) | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) | Total |
|---|---|---|---|---|---|---|
| Mean | 55.6 ± 4.1 | 55.4 ± 4.0 | 55.9 ± 4.2 | 54.8 ± 4.4 | 55.0 ± 3.8 | 55.1 ± 4.1 |
| Sex: Female, Male(Participants) | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) | Total |
|---|---|---|---|---|---|---|
| Female | 47 | 31 | 17 | 52 | 52 | 199 |
| Male | 0 | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 2 | 1 | 2 | 6 | 13 |
| Not Hispanic or Latino | 45 | 29 | 16 | 50 | 46 | 186 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | 40 mg Elinzanetant (BAY3427080) | 80 mg Elinzanetant (BAY3427080) | 120 mg Elinzanetant (BAY3427080) | 160 mg Elinzanetant (BAY3427080) | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 2 | 0 | 0 | 1 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 6 | 5 | 3 | 13 | 11 | 38 |
| White | 38 | 24 | 13 | 37 | 40 | 152 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 2 | 1 | 1 | 0 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Ran from Nov 2018 to primary completion in Nov 2019, 12 months.
Results were first posted in Mar 2023, 3 years 3 months after primary completion. A results delay was requested in Nov 2020.
Of 24 phase 2 interventional studies under Hot Flashes, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 54. This study's 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elinzanetant